<?xml version="1.0" encoding="UTF-8"?>
<search_results count="309">
  <query>PegIntron</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT00723892</nct_id>
    <title>Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PegIntron)</intervention>
      <intervention type="Drug">Rebetol (Ribavirin)</intervention>
      <intervention type="Behavioral">Psychotherapy support program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>614</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04252</other_id>
      <other_id>MK-4031-245</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>July 2005</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 25, 2010</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.</outcome_measure>
      <outcome_measure>the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723892</url>
  </study>
  <study rank="2">
    <nct_id>NCT00728494</nct_id>
    <title>Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
      <intervention type="Behavioral">Patient Assistance Program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04671</other_id>
    </other_ids>
    <first_received>July 31, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C</outcome_measure>
      <outcome_measure>The Number of Participants With a Sustained Virologic Response at 6 Months Post-treatment</outcome_measure>
      <outcome_measure>The Number of Participants Who Relapsed at 6 Months Post-treatment</outcome_measure>
      <outcome_measure>Average Length of Treatment</outcome_measure>
      <outcome_measure>Average Dosage of PegIntron</outcome_measure>
      <outcome_measure>Average Dosage of Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00728494</url>
  </study>
  <study rank="3">
    <nct_id>NCT00787371</nct_id>
    <title>Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04508</other_id>
      <other_id>JPC-04-356-20</other_id>
    </other_ids>
    <first_received>November 6, 2008</first_received>
    <start_date>June 2005</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who achieve normalization of ALT in each treatment group</outcome_measure>
      <outcome_measure>Safety: adverse events, adverse reactions, laboratory test result (hematology, blood biochemistry and thyroid function test)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00787371</url>
  </study>
  <study rank="4">
    <nct_id>NCT00371761</nct_id>
    <title>PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic (CHB)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon alfa-2b (PegIntron)</intervention>
      <intervention type="Drug">Adefovir dipivoxil (adefovir)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04498</other_id>
    </other_ids>
    <first_received>August 31, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>July 15, 2010</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00371761</url>
  </study>
  <study rank="5">
    <nct_id>NCT00726557</nct_id>
    <title>Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Substance Abuse, Intravenous</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (pegylated interferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04408</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>April 15, 2010</firstreceived_results_date>
    <acronym>SUPPORT</acronym>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Drug-substituted Participants Who Achieved Sustained Virological Response (SVR) With PegIntron 1.5 μg/kg/Week and Rebetol (10.6 mg/kg/Day) in Substitution Centers Under Routine Conditions</outcome_measure>
      <outcome_measure>Number of Participants Who Tolerated Treatment With PegIntron 1.5 mcg/kg/Week + Rebetol 10.6 mg/kg/Week</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00726557</url>
  </study>
  <study rank="6">
    <nct_id>NCT02343224</nct_id>
    <title>PEG-Intron for Recurrent or Refractory Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Juvenile Pilocytic Astrocytomas</condition>
      <condition>Optic Pathway Gliomas</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>CURE Childhood Cancer, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00074563</other_id>
    </other_ids>
    <first_received>January 8, 2015</first_received>
    <start_date>November 2014</start_date>
    <completion_date>December 2021</completion_date>
    <last_updated>August 11, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEG-Intron</acronym>
    <primary_completion_date>December 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in response rate of subjects to Peg-Intron from baseline to 2 years</outcome_measure>
      <outcome_measure>Event Free Survival</outcome_measure>
      <outcome_measure>Change in toxicity, collected using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 of the National Cancer Institute (NCI)</outcome_measure>
      <outcome_measure>Change in Quality of Life, assessed by using the Functional Assessment of Cancer Therapy-Brain (Peds-FACT-Br) questionnaire</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02343224</url>
  </study>
  <study rank="7">
    <nct_id>NCT00725205</nct_id>
    <title>Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (Peginterferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04690</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>March 2006</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Are Triple-80 Compliant</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number Of Participants Self-Administering Pegylated Interferon Alfa-2b</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725205</url>
  </study>
  <study rank="8">
    <nct_id>NCT00723879</nct_id>
    <title>Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Behavioral">Patient assistance program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04206</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>October 2004</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who complete treatment with PegIntron plus Rebetol therapy for hepatitis C when administered with a patient assistance program.</outcome_measure>
      <outcome_measure>Average length of treatment for patients receiving a patient assistance program as part of their treatment for hepatitis C with PegIntron plus Rebetol.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723879</url>
  </study>
  <study rank="9">
    <nct_id>NCT00705263</nct_id>
    <title>Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Schering-Plough</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>113</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04244</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>August 20, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>May 28, 2009</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705263</url>
  </study>
  <study rank="10">
    <nct_id>NCT00704717</nct_id>
    <title>Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031) pen</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04301</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>April 8, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>February 11, 2009</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704717</url>
  </study>
  <study rank="11">
    <nct_id>NCT00704964</nct_id>
    <title>Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron</intervention>
      <intervention type="Drug">Rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>746</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04413</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2005</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 24, 2011</firstreceived_results_date>
    <acronym>@dhere</acronym>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Biometrical Adherence to Therapy</outcome_measure>
      <outcome_measure>Number of Participants With Adherence to Therapy According to Physician Approximation</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704964</url>
  </study>
  <study rank="12">
    <nct_id>NCT00704522</nct_id>
    <title>Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Behavioral">Patient assistance program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04281</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>March 2005</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>April 21, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program</outcome_measure>
      <outcome_measure>Average Length of Treatment With PegIntron/Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704522</url>
  </study>
  <study rank="13">
    <nct_id>NCT00441584</nct_id>
    <title>The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03833</other_id>
      <other_id>ESPECIAL</other_id>
    </other_ids>
    <first_received>February 28, 2007</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00441584</url>
  </study>
  <study rank="14">
    <nct_id>NCT00736242</nct_id>
    <title>Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-IFN alfa-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04584</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 21, 2012</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Participant Study Status at End of Follow-up (EOF)</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis C Virus (HCV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Number of Participants With Human Immunodeficiency Virus (HIV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Median Cluster of Differentiation 4 (CD4) Cell Count During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Number of Participants With A Serious Adverse Event (SAE) During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00736242</url>
  </study>
  <study rank="15">
    <nct_id>NCT00727311</nct_id>
    <title>Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031) injector</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2302</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04538</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>August 2005</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>December 22, 2010</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of HCV-RNA Negative Participants at Follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00727311</url>
  </study>
  <study rank="16">
    <nct_id>NCT01740089</nct_id>
    <title>Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEG-IFNа-2</other_id>
    </other_ids>
    <first_received>November 30, 2012</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>March 1, 2015</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.</outcome_measure>
      <outcome_measure>Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) After 4 Weeks of Treatment.</outcome_measure>
      <outcome_measure>Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.</outcome_measure>
      <outcome_measure>Number of Patients Who Have Undetectable HCV RNA (&lt; 15 IU/ml) at the End of Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01740089</url>
  </study>
  <study rank="17">
    <nct_id>NCT01340573</nct_id>
    <title>Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron Pen</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04896</other_id>
    </other_ids>
    <first_received>November 18, 2010</first_received>
    <start_date>March 2007</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>January 20, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>October 4, 2011</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-48 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Non-genotype 1 Participants Who Experienced Serious Adverse Events (SAE) on Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-48 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Participants' Overall Rating of Satisfaction and the Use of Training Materials for the Pegintron Pen, as Provided in a Study Questionnaire</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01340573</url>
  </study>
  <study rank="18">
    <nct_id>NCT00160251</nct_id>
    <title>Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Biological">PegIntron (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>357</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03659</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</outcome_measure>
      <outcome_measure>Percent of Participants With Virologic Response Prior to Amendment 2</outcome_measure>
      <outcome_measure>Peak Plasma Concentration of Boceprevir (BOC)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</outcome_measure>
      <outcome_measure>Trough Plasma Concentration Level</outcome_measure>
      <outcome_measure>Change in Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00160251</url>
  </study>
  <study rank="19">
    <nct_id>NCT01054742</nct_id>
    <title>Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Standard of Care PegIntron</intervention>
      <intervention type="Drug">Standard of Care Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04793 Part 2</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>January 7, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>May 15, 2012</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Levels During Part 2 of the Study</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01054742</url>
  </study>
  <study rank="20">
    <nct_id>NCT02103439</nct_id>
    <title>An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C/ Human Immunodeficiency Virus Coinfection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">PegIntron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BCD-016-4</other_id>
    </other_ids>
    <first_received>April 1, 2014</first_received>
    <start_date>September 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>May 21, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>Early Virological Response in Patients With Different Hepatitis C Virus Genotypes</outcome_measure>
      <outcome_measure>Rapid Virological Response</outcome_measure>
      <outcome_measure>Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes</outcome_measure>
      <outcome_measure>Viral Breakthrough</outcome_measure>
      <outcome_measure>Biochemical Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02103439</url>
  </study>
  <study rank="21">
    <nct_id>NCT00302081</nct_id>
    <title>Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>696</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03548</other_id>
    </other_ids>
    <first_received>March 10, 2006</first_received>
    <start_date>August 2003</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 29, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Who Achieve a Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Virologic Response Rates at the End of Therapy. Biochemical Responses as Determined by ALT and AST Levels at the End of Treatment and at the End of Follow up.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00302081</url>
  </study>
  <study rank="22">
    <nct_id>NCT00727259</nct_id>
    <title>Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1995</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04067</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>October 2004</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
    <acronym>SATISFACTION</acronym>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00727259</url>
  </study>
  <study rank="23">
    <nct_id>NCT00081770</nct_id>
    <title>Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">REBETOL (ribavirin; SCH 18908)</intervention>
      <intervention type="Biological">PEGASYS (peginterferon alfa-2a)</intervention>
      <intervention type="Drug">COPEGUS (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4469</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03471</other_id>
      <other_id>2552898</other_id>
    </other_ids>
    <first_received>April 20, 2004</first_received>
    <start_date>March 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 31, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 3, 2008</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</outcome_measure>
      <outcome_measure>Virologic Response Rate at Treatment Week 12</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00081770</url>
  </study>
  <study rank="24">
    <nct_id>NCT00709059</nct_id>
    <title>Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>538</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04243</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>December 22, 2010</firstreceived_results_date>
    <acronym>PRACTICE</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Study Participants Who Had a Virological Response (VR) at Week-72</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00709059</url>
  </study>
  <study rank="25">
    <nct_id>NCT00705666</nct_id>
    <title>Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>789</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04437</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>February 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 30, 2010</firstreceived_results_date>
    <acronym>ADEQUATION</acronym>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705666</url>
  </study>
  <study rank="26">
    <nct_id>NCT01387763</nct_id>
    <title>A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
      <condition>Essential Thrombocythemia</condition>
      <condition>Primary Myelofibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Hydrea</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Stauffer Larsen</lead_sponsor>
      <collaborator>Odense University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>daliah2011</other_id>
    </other_ids>
    <first_received>June 23, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>April 20, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DALIAH</acronym>
    <primary_completion_date>January 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>molecular response (changes from baseline)</outcome_measure>
      <outcome_measure>toxicity (discontinuation of therapy due to intolerability)</outcome_measure>
      <outcome_measure>Quality of life (changes from baseline)</outcome_measure>
      <outcome_measure>Histopathological response (changes from baseline)</outcome_measure>
      <outcome_measure>Sustained molecular response (changes from level at time of discontinuation of therapy)</outcome_measure>
      <outcome_measure>Neutralizing antibodies against PegIntron and Pegasys</outcome_measure>
      <outcome_measure>hematological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01387763</url>
  </study>
  <study rank="27">
    <nct_id>NCT00723931</nct_id>
    <title>PegIntron Injection Surveillance Plan (Study P04123)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1267</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04123</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>June 2006</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>November 9, 2010</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants That Reported a Serious Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants That Reported a Non Serious Adverse Event Above 5 Percent Threshold</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723931</url>
  </study>
  <study rank="28">
    <nct_id>NCT00686790</nct_id>
    <title>Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis D, Chronic</condition>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PegIntron, SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04603</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>December 21, 2010</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Virological Response</outcome_measure>
      <outcome_measure>Number of Participants With a Biochemical Response</outcome_measure>
      <outcome_measure>Number of Participants With a Combined Response</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)</outcome_measure>
      <outcome_measure>Number of Participants With a Liver Histology Response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686790</url>
  </study>
  <study rank="29">
    <nct_id>NCT00724295</nct_id>
    <title>Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1077</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04505</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>April 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>February 3, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall incidence of adverse events and adverse drug reactions.</outcome_measure>
      <outcome_measure>Assessment of trends of adverse drug reactions by patient factors and concomitant medications. Incidence of adverse events (AEs) in the elderly vs younger patients; rates of hematologic AEs; dose reduction and discontinuation rates.</outcome_measure>
      <outcome_measure>Sustained virologic response rate and improvement of ALT (alanine transaminase).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724295</url>
  </study>
  <study rank="30">
    <nct_id>NCT00724854</nct_id>
    <title>Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05427</other_id>
      <other_id>001/05</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 23, 2010</firstreceived_results_date>
    <acronym>APEGIN</acronym>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With RVR Who Also Achieved SVR</outcome_measure>
      <outcome_measure>Assessment of Response at Treatment Week 48 for Genotypes 2 and 3, and Treatment Week 72 for Genotypes 1, 4, and 5, in Participants With RVR</outcome_measure>
      <outcome_measure>Assessment of Baseline Characteristics in Participants With SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724854</url>
  </study>
  <study rank="31">
    <nct_id>NCT00705107</nct_id>
    <title>Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron pen (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>267</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04247</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>November 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>February 11, 2009</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Completed Treatment.</outcome_measure>
      <outcome_measure>Average Length of Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705107</url>
  </study>
  <study rank="32">
    <nct_id>NCT00207363</nct_id>
    <title>Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin, Peg interferon alfa 2b</intervention>
      <intervention type="Drug">induction therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
      <collaborator>T.R.U.E. Research Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>610</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C2002.076</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>February 2002</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of this study is to compare the efficacy of Induction PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) to standard PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) in patients with chronic hepatitis C.</outcome_measure>
      <outcome_measure>The loss of HCV-RNA at 6 months of follow up. If the HCV-RNA has not decreased by one log at treatment week 24, the patient will be classified as a treatment nonresponder and medications are discontinued.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00207363</url>
  </study>
  <study rank="33">
    <nct_id>NCT00724230</nct_id>
    <title>Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>505</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04841</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>February 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall incidence of adverse events and adverse drug reactions.</outcome_measure>
      <outcome_measure>Assessment of trends of adverse drug reactions by patient factors and concomitant medications; Incidence, severity, and outcome of adverse events (AEs) between the elderly vs younger patients</outcome_measure>
      <outcome_measure>Sustained virologic response rate by HCV genotype, baseline viral load, and patient demographic characteristics</outcome_measure>
      <outcome_measure>Rate of ALT normalization at end of treatment period and at 24 weeks post completing therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724230</url>
  </study>
  <study rank="34">
    <nct_id>NCT00457418</nct_id>
    <title>High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04831</other_id>
    </other_ids>
    <first_received>April 5, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>February 12, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>May 28, 2013</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Curve (AUC) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced an Adverse Event (AE)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00457418</url>
  </study>
  <study rank="35">
    <nct_id>NCT00048724</nct_id>
    <title>Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>631</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02569</other_id>
    </other_ids>
    <first_received>November 6, 2002</first_received>
    <start_date>June 2002</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>April 23, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Observation of the First Clinical Event Experienced by a Subject</outcome_measure>
      <outcome_measure>Time to Observation of the Disease Progression Experienced by a Subject</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00048724</url>
  </study>
  <study rank="36">
    <nct_id>NCT01641926</nct_id>
    <title>A Study of the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Participants With Chronic Hepatitis B (P08450)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-Intron™</intervention>
      <intervention type="Biological">PEGASYS™</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>402</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08450</other_id>
      <other_id>MK-4031-376</other_id>
    </other_ids>
    <first_received>July 11, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>November 26, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of HBeAg(+) participants achieving HBeAg seroconversion at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(-) participants achieving hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving HBV DNA &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving alanine aminotransferase (ALT) normalization at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving the combined response of HBeAg seroconversion and HBV DNA &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641926</url>
  </study>
  <study rank="37">
    <nct_id>NCT00724464</nct_id>
    <title>Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05209</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 4, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number of Participants Who Demonstrated Virological Relapse as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV Genotype at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Liver Fibrosis Stage at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV-RNA Viral Load at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Alanine Aminotransferase (ALT) Levels at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Study Treatment Dosage Modification</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Achievement of Rapid Virological Response</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Compliance With the 80/80/80 Rule</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724464</url>
  </study>
  <study rank="38">
    <nct_id>NCT00085384</nct_id>
    <title>PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fallopian Tube Cancer</condition>
      <condition>Ovarian Cancer</condition>
      <condition>Peritoneal Cavity Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">PEG-interferon alfa-2b</intervention>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID02-115</other_id>
      <other_id>P50CA083639</other_id>
      <other_id>P30CA016672</other_id>
      <other_id>MDA-ID-02115</other_id>
      <other_id>CDR0000368964</other_id>
    </other_ids>
    <first_received>June 10, 2004</first_received>
    <start_date>July 2002</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>August 1, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Optimal Biologic Dose at 8 weeks</outcome_measure>
      <outcome_measure>Tumor Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00085384</url>
  </study>
  <study rank="39">
    <nct_id>NCT00221702</nct_id>
    <title>PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
      <condition>Neoplasm Metastasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">intron A</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>898</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9267-01</other_id>
      <other_id>2001-034</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>June 2003</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>October 12, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EADO</acronym>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>disease-free survival time</outcome_measure>
      <outcome_measure>time to distant metastasis</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
      <outcome_measure>toxicity</outcome_measure>
      <outcome_measure>quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221702</url>
  </study>
  <study rank="40">
    <nct_id>NCT00589550</nct_id>
    <title>PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Kidney Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">Sorafenib</intervention>
      <intervention type="Genetic">gene expression analysis</intervention>
      <intervention type="Genetic">polymerase chain reaction</intervention>
      <intervention type="Genetic">reverse transcriptase-polymerase chain reaction</intervention>
      <intervention type="Other">flow cytometry</intervention>
      <intervention type="Other">immunoenzyme technique</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Olencki</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Ohio State University Comprehensive Cancer Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>OSU-06113</other_id>
    </other_ids>
    <first_received>January 5, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 6, 2015</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Tolerated Dose of PEG-interferon Alfa-2b and Sorafenib Tosylate</outcome_measure>
      <outcome_measure>Characterize the Toxicity of Peginterferon Alfa-2b and Sorafenib in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma.</outcome_measure>
      <outcome_measure>Progression-free Survival of Patients Receiving Peginterferon Alfa-2b and Sorafenib.</outcome_measure>
      <outcome_measure>Response Rate of Patients Receiving Peginterferon Alfa-2b and Sorafenib.</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Activation of Interferon-induced Transcription Factors in Immune Cell Subsets by Flow Cytometry and Correlation of This Information With Clinical Outcome</outcome_measure>
      <outcome_measure>Circulating Levels of IFN-γ and IL-5 for Determination of Th1/Th2 Status and CD4+, CD25+, and FoxP3 Cell Number (T Regs) in Peripheral Blood</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00589550</url>
  </study>
  <study rank="41">
    <nct_id>NCT00255008</nct_id>
    <title>Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04212</other_id>
    </other_ids>
    <first_received>November 15, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>February 4, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Achieved a Sustained Virologic Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00255008</url>
  </study>
  <study rank="42">
    <nct_id>NCT00536263</nct_id>
    <title>PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha-2b</intervention>
      <intervention type="Drug">pegylated interferon alpha-2b</intervention>
      <intervention type="Drug">pegylated interferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>671</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05170</other_id>
    </other_ids>
    <first_received>September 26, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>November 23, 2010</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss</outcome_measure>
      <outcome_measure>Number of Participants With HBeAg Loss</outcome_measure>
      <outcome_measure>HBe Seroconversion</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) &lt;20,000 IU/mL</outcome_measure>
      <outcome_measure>Number of Participants With HBV-DNA &lt; 200 IU/mL</outcome_measure>
      <outcome_measure>Number of Participants With HBV-DNA Undetectable</outcome_measure>
      <outcome_measure>Number of Participants With Biochemical Response</outcome_measure>
      <outcome_measure>Number of Participants With Combined Response</outcome_measure>
      <outcome_measure>Hepatitis B Surface Antigen (HBsAg) Loss</outcome_measure>
      <outcome_measure>Hepatitis B Surface Antigen (HBs) Seroconversion</outcome_measure>
      <outcome_measure>Change From Baseline in Liver Biopsy Score</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00536263</url>
  </study>
  <study rank="43">
    <nct_id>NCT00037882</nct_id>
    <title>PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leukemia, Myeloid, Philadelphia-Positive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DM00-150</other_id>
    </other_ids>
    <first_received>May 24, 2002</first_received>
    <start_date>February 2001</start_date>
    <completion_date>December 2003</completion_date>
    <last_updated>July 31, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00037882</url>
  </study>
  <study rank="44">
    <nct_id>NCT00687544</nct_id>
    <title>Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 054031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 018908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04469</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 22, 2011</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Virologic Response (VR)</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Biochemical Response (SBR)</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Opportunistic Infection</outcome_measure>
      <outcome_measure>Number of Participants Who Died</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00687544</url>
  </study>
  <study rank="45">
    <nct_id>NCT00039871</nct_id>
    <title>PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Fibrosis</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">REBETOL (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2333</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02370</other_id>
    </other_ids>
    <first_received>June 13, 2002</first_received>
    <start_date>May 2002</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>September 29, 2008</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00039871</url>
  </study>
  <study rank="46">
    <nct_id>NCT01325896</nct_id>
    <title>Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Mieloma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron sc injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitario de la Princesa</lead_sponsor>
      <collaborator>Haematology Service,</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI-MM-01</other_id>
    </other_ids>
    <first_received>March 11, 2011</first_received>
    <start_date>September 2002</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>March 30, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale</outcome_measure>
      <outcome_measure>Increase of Response (anti-tumoral effect) and Dose Tolerance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01325896</url>
  </study>
  <study rank="47">
    <nct_id>NCT00704756</nct_id>
    <title>An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05494</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>January 2009</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>August 8, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGIMPACT</acronym>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety parameters: common adverse events [AEs], drug-to-drug interaction AEs, and dose modifications</outcome_measure>
      <outcome_measure>Relapse rates and Sustained Virologic Response (SVR) rates and their association with demographic, virologic, histological, and safety parameters</outcome_measure>
      <outcome_measure>Predictors of response at End-of-Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704756</url>
  </study>
  <study rank="48">
    <nct_id>NCT00588146</nct_id>
    <title>Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Anemia</condition>
      <condition>Liver Disease</condition>
      <condition>Hypoxemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon Alpha2b</intervention>
      <intervention type="Other">Standard care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Georgia Regents University</collaborator>
      <collaborator>St. Michael's Hospital, Toronto</collaborator>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2400-05</other_id>
      <other_id>R01FD003076-01</other_id>
    </other_ids>
    <first_received>December 26, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>February 19, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>December 20, 2012</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Hemoglobin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00588146</url>
  </study>
  <study rank="49">
    <nct_id>NCT00050531</nct_id>
    <title>High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leukemia, Myeloid, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gleevec</intervention>
      <intervention type="Drug">Peg-alpha interferon (Peg-Intron)</intervention>
      <intervention type="Drug">Sargramostim (GM-CSF)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID02-534</other_id>
      <other_id>NCI-2012-01295</other_id>
    </other_ids>
    <first_received>December 12, 2002</first_received>
    <start_date>April 2003</start_date>
    <last_updated>August 17, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Durations of Pathologic Complete Response (PCR) Negativity, Cytogenetic Response, Hematologic Control, and Survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00050531</url>
  </study>
  <study rank="50">
    <nct_id>NCT01945294</nct_id>
    <title>Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-107</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at TW 8 Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 By Virologic Response At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Neutrophil Count &lt;0.75 x10^9/L</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Dose Discontinuation/Modification Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment-Related Serious AEs (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945294</url>
  </study>
  <study rank="51">
    <nct_id>NCT00525031</nct_id>
    <title>Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Temozolomide (TMZ)</intervention>
      <intervention type="Drug">Pegylated Interferon Alpha-2b (PGI)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-0143</other_id>
      <other_id>NCI-2010-00855</other_id>
    </other_ids>
    <first_received>August 31, 2007</first_received>
    <start_date>August 2006</start_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pathological Response Rates (pCR+ pPR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00525031</url>
  </study>
  <study rank="52">
    <nct_id>NCT00265395</nct_id>
    <title>Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)</intervention>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1428</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03685</other_id>
      <other_id>SUCCESS</other_id>
    </other_ids>
    <first_received>December 13, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 15, 2009</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00265395</url>
  </study>
  <study rank="53">
    <nct_id>NCT01496807</nct_id>
    <title>Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sylatron</intervention>
      <intervention type="Drug">Yervoy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCC-16755</other_id>
    </other_ids>
    <first_received>December 19, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Tolerated Dose (MTD)</outcome_measure>
      <outcome_measure>Rate of Induction of Autoimmune Antibodies</outcome_measure>
      <outcome_measure>Number of Participants With Overall Response (OR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01496807</url>
  </study>
  <study rank="54">
    <nct_id>NCT00746746</nct_id>
    <title>A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">HyperAcute vaccine</intervention>
      <intervention type="Drug">Pegylated Interferon-Alpha 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ochsner Health System</lead_sponsor>
      <collaborator>NewLink Genetics Corporation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>USA-MCI-01</other_id>
      <other_id>IND# 13647</other_id>
    </other_ids>
    <first_received>September 3, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>January 12, 2011</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To conduct scientific studies of patient tumor and peripheral blood samples to determine the mechanism of any observed anti-tumor effect involving the immune responses to the HyperAcute® vaccine alone &amp; combined with PEG-Intron</outcome_measure>
      <outcome_measure>To determine the safety and response rate of the administration of the HyperAcute®-Melanoma Vaccine combined with PEG-Intron® into patients with recurrent, refractory, metastatic, or high risk of recurrence melanoma</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Louisiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00746746</url>
  </study>
  <study rank="55">
    <nct_id>NCT00255034</nct_id>
    <title>Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04143</other_id>
    </other_ids>
    <first_received>November 15, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>March 30, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>June 4, 2009</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00255034</url>
  </study>
  <study rank="56">
    <nct_id>NCT00276523</nct_id>
    <title>PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Head and Neck Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Procedure">Conventional surgery</intervention>
      <intervention type="Procedure">Neoadjuvant therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000441020</other_id>
      <other_id>MDA-ID-01450</other_id>
      <other_id>ID01-450</other_id>
    </other_ids>
    <first_received>January 12, 2006</first_received>
    <start_date>February 2004</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>October 29, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response rate</outcome_measure>
      <outcome_measure>Toxicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00276523</url>
  </study>
  <study rank="57">
    <nct_id>NCT00415857</nct_id>
    <title>Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peptide Vaccine (PR1 Peptide)</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Imatinib</intervention>
      <intervention type="Drug">GM-CSF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>The Vaccine Company</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-0360</other_id>
    </other_ids>
    <first_received>December 22, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>March 28, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>March 28, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Molecular Response Rate</outcome_measure>
      <outcome_measure>Number of Participants With Immunologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00415857</url>
  </study>
  <study rank="58">
    <nct_id>NCT00761735</nct_id>
    <title>5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02538: Part 2</other_id>
      <other_id>2004-000558-22</other_id>
    </other_ids>
    <first_received>September 5, 2008</first_received>
    <start_date>July 2007</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 28, 2013</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Relapsed At End of LTFU Year 5</outcome_measure>
      <outcome_measure>Mean Height Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Weight Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00761735</url>
  </study>
  <study rank="59">
    <nct_id>NCT01081158</nct_id>
    <title>Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)</intervention>
      <intervention type="Drug">Drug: SCH 900518 Biologic: Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)</intervention>
      <intervention type="Drug">Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04695</other_id>
    </other_ids>
    <first_received>March 3, 2010</first_received>
    <start_date>July 2007</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability were to be assessed by collecting adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, urinalysis, and safety laboratory tests.</outcome_measure>
      <outcome_measure>Log change in HCV-RNA from baseline. Ctrough of SCH 900518 resulting in mean HCV RNA decrease &gt; 2 log10 IU/mL. Ctrough of SCH 900518+PEG resulting in HCV-RNA &lt; LOQ. SCH 900518 PK: Cmax, Tmax, AUC, Ctrough, t½, R, CL/F, Vd/F. PEG and RTV: Ctrough</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01081158</url>
  </study>
  <study rank="60">
    <nct_id>NCT00237484</nct_id>
    <title>Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin</intervention>
      <intervention type="Drug">Combination of (a) pegylated interferon alfa-2b and (b) ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04257</other_id>
    </other_ids>
    <first_received>October 10, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Pegade</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end</outcome_measure>
      <outcome_measure>Early virological response (EVR)</outcome_measure>
      <outcome_measure>Safety parameters</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00237484</url>
  </study>
  <study rank="61">
    <nct_id>NCT00723632</nct_id>
    <title>Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>901</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04588</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>November 11, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category</outcome_measure>
      <outcome_measure>Average Cost Per Participant With SVR Stratified by Ribavirin Dosage</outcome_measure>
      <outcome_measure>Average Cost Per Participant With SVR Stratified by Prior Treatment Status</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723632</url>
  </study>
  <study rank="62">
    <nct_id>NCT00803309</nct_id>
    <title>Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated Interferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>HepNet Study House, German Liverfoundation</lead_sponsor>
      <collaborator>Hannover Clinical Trial Center GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05498</other_id>
    </other_ids>
    <first_received>December 4, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>March 18, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPTEX2/3</acronym>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)</outcome_measure>
      <outcome_measure>Virological response rates (HCV-RNA negative in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) at the end of therapy</outcome_measure>
      <outcome_measure>Biochemical responses as determined by ALT and AST levels at the end of treatment and at the end of follow up.</outcome_measure>
      <outcome_measure>Severity and frequency of adverse event</outcome_measure>
      <outcome_measure>Analysis of quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00803309</url>
  </study>
  <study rank="63">
    <nct_id>NCT00179413</nct_id>
    <title>Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>Advanced Fibrosis</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG interferon Alfa-2b; Colchicine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2001-P-000002</other_id>
    </other_ids>
    <first_received>September 10, 2005</first_received>
    <start_date>January 2001</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>June 23, 2006</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Determination of the effect of PEG-Intron 0.5mg per kg weekly sc versus colchicine 0.6mg bid daily on:</outcome_measure>
      <outcome_measure>4 year survival or hepatic transplantation</outcome_measure>
      <outcome_measure>Variceal or portal hypertensive bleeding</outcome_measure>
      <outcome_measure>Development of jaundice, ascites or encephalopathy with an increase in CPT of &gt; 2 points</outcome_measure>
      <outcome_measure>Development of hepatoma</outcome_measure>
      <outcome_measure>Evaluation of safety and tolerability of long term maintenance PEG-Intron in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluation of the effect of long term maintenance PEG-Intron on quality of life</outcome_measure>
      <outcome_measure>Evaluation of surrogate markers of fibrosis in determining effect of long term maintenance PEG-Intron on prevention of progression of fibrosis and correlation of fibrosis markers with pathology.</outcome_measure>
      <outcome_measure>Development of portal hypertension</outcome_measure>
      <outcome_measure>Progression of histological fibrosis</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00179413</url>
  </study>
  <study rank="64">
    <nct_id>NCT00724620</nct_id>
    <title>PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 054031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 018908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Schering-Plough</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04511</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>June 2005</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>July 25, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the overall SVR of chronic hepatitis C Genotype 1 Naïve Mexican patients with different durations of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724620</url>
  </study>
  <study rank="65">
    <nct_id>NCT00104052</nct_id>
    <title>Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (PEG2b) (SCH 54031)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02538: Part 1</other_id>
    </other_ids>
    <first_received>February 22, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 14, 2008</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00104052</url>
  </study>
  <study rank="66">
    <nct_id>NCT01590225</nct_id>
    <title>Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08034</other_id>
      <other_id>2010-024260-17</other_id>
    </other_ids>
    <first_received>May 1, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>August 2021</completion_date>
    <last_updated>February 20, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants Achieving Sustained Viral Response (SVR) at Follow-Up Week 24 in Study Part A</outcome_measure>
      <outcome_measure>Participants Achieving SVR at Follow-Up Week 24 in Study Part B</outcome_measure>
      <outcome_measure>Time to Viral Relapse in Study Part C</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part A</outcome_measure>
      <outcome_measure>Participants With Early Virologic Response in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs) in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Treatment-Related AEs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Serious AEs (SAEs) in Study Part A</outcome_measure>
      <outcome_measure>Participants Discontinuing Treatment Due to AEs in Study Part A</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part A</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing AEs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing SAEs in Study Part B</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part B</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Treatment Due to AEs in Study Part B</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01590225</url>
  </study>
  <study rank="67">
    <nct_id>NCT00055809</nct_id>
    <title>Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metastatic Gastrointestinal Carcinoid Tumor</condition>
      <condition>Recurrent Gastrointestinal Carcinoid Tumor</condition>
      <condition>Regional Gastrointestinal Carcinoid Tumor</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Biological">bevacizumab</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCI-2012-02519</other_id>
      <other_id>MDA-ID-02063</other_id>
      <other_id>N01CM62202</other_id>
      <other_id>CDR0000271225</other_id>
    </other_ids>
    <first_received>March 6, 2003</first_received>
    <start_date>January 2003</start_date>
    <last_updated>January 22, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tumor response rate (CR + PR) as measured by RECIST criteria</outcome_measure>
      <outcome_measure>Progression free survival</outcome_measure>
      <outcome_measure>Biochemical response rate measured after treatment</outcome_measure>
      <outcome_measure>Toxicity graded according to CTC v3.0 criteria for adverse outcomes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00055809</url>
  </study>
  <study rank="68">
    <nct_id>NCT00791271</nct_id>
    <title>Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Decitabine</intervention>
      <intervention type="Drug">Pegylated Interferon Alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007-0450</other_id>
      <other_id>NCI-2010-01030</other_id>
    </other_ids>
    <first_received>November 12, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase I: Dose-limiting toxicity (DLT)</outcome_measure>
      <outcome_measure>Phase II: Patient Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00791271</url>
  </study>
  <study rank="69">
    <nct_id>NCT02605473</nct_id>
    <title>Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Decitabine</intervention>
      <intervention type="Drug">Pegylated Interferon Alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Eisai Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007-0450 Phase II</other_id>
      <other_id>NCI-2010-01030</other_id>
    </other_ids>
    <first_received>November 12, 2015</first_received>
    <start_date>September 2008</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>November 13, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02605473</url>
  </study>
  <study rank="70">
    <nct_id>NCT00018031</nct_id>
    <title>Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>010194</other_id>
      <other_id>01-I-0194</other_id>
    </other_ids>
    <first_received>June 27, 2001</first_received>
    <start_date>June 2001</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>January 18, 2013</firstreceived_results_date>
    <acronym>HEPCPR</acronym>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Viral Decline at Day 3 &amp; 28 With Predictors of Post Treatment Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00018031</url>
  </study>
  <study rank="71">
    <nct_id>NCT00035360</nct_id>
    <title>Phase III PEG-Intron in HIV-infected Patients (Study P00738)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>P00738</other_id>
    </other_ids>
    <first_received>May 2, 2002</first_received>
    <start_date>March 2002</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00035360</url>
  </study>
  <study rank="72">
    <nct_id>NCT00202839</nct_id>
    <title>Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04144</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>August 28, 2009</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Virologic Response 48 Weeks After Randomization.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00202839</url>
  </study>
  <study rank="73">
    <nct_id>NCT01683786</nct_id>
    <title>36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegintron + Riba</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MISP39068</other_id>
    </other_ids>
    <first_received>January 31, 2012</first_received>
    <start_date>August 2011</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 11, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of sustained virologic response</outcome_measure>
      <outcome_measure>the factors associated with sustained virologic response(SVR) between groups</outcome_measure>
      <outcome_measure>the rate of end-of-treatment response(EOT)</outcome_measure>
      <outcome_measure>The relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01683786</url>
  </study>
  <study rank="74">
    <nct_id>NCT00303290</nct_id>
    <title>PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg Interferon Alpha 2b (Peg Intron)</intervention>
      <intervention type="Drug">Ara-C (cytosine arabinoside)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DM99-127</other_id>
      <other_id>NCI-2010-00887</other_id>
    </other_ids>
    <first_received>March 15, 2006</first_received>
    <start_date>January 2000</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 25, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Complete Cytogenetic Response Rate after One Year on Therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00303290</url>
  </study>
  <study rank="75">
    <nct_id>NCT00378599</nct_id>
    <title>Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of (a) pegylated interferon alfa-2b and (b) rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04590</other_id>
    </other_ids>
    <first_received>September 18, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>June 17, 2010</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00378599</url>
  </study>
  <study rank="76">
    <nct_id>NCT00709228</nct_id>
    <title>Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>496</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04793</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2006</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>November 9, 2009</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of HCV LVL G1 Participants Who Relapsed</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00709228</url>
  </study>
  <study rank="77">
    <nct_id>NCT01532843</nct_id>
    <title>Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV 11-02</other_id>
    </other_ids>
    <first_received>February 10, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGON</acronym>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01532843</url>
  </study>
  <study rank="78">
    <nct_id>NCT01641666</nct_id>
    <title>Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b 1.5 mcg/kg/week</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08599</other_id>
    </other_ids>
    <first_received>July 11, 2012</first_received>
    <start_date>May 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641666</url>
  </study>
  <study rank="79">
    <nct_id>NCT00724373</nct_id>
    <title>Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>442</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05269</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>November 2007</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 6, 2010</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Treatment Success</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724373</url>
  </study>
  <study rank="80">
    <nct_id>NCT00593151</nct_id>
    <title>Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Locteron (controlled-release interferon alpha 2b)</intervention>
      <intervention type="Biological">pegylated IFNa2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>S07-200-02-003</other_id>
    </other_ids>
    <first_received>January 2, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PLUS</acronym>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess in subjects with chronic hepatitis C the safety and tolerability of Locteron in comparison with PEG-Intron.</outcome_measure>
      <outcome_measure>To assess in subjects with chronic hepatitis C receiving a weight-based oral daily dose of ribavirin: • The PK profile of Locteron (IFNa2b) • The preliminary efficacy of Locteron assessed by serial quantitation of HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00593151</url>
  </study>
  <study rank="81">
    <nct_id>NCT00861406</nct_id>
    <title>Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon-Alfa 2b (PEG Intron)</intervention>
      <intervention type="Drug">GP-100 Peptide Vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-0816</other_id>
      <other_id>NCI-2012-01652</other_id>
    </other_ids>
    <first_received>March 12, 2009</first_received>
    <start_date>March 2009</start_date>
    <last_updated>April 23, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patient Maximum T-cell Levels During 24-Week Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00861406</url>
  </study>
  <study rank="82">
    <nct_id>NCT01290679</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017380</other_id>
      <other_id>TMC435-TiDP16-C216</other_id>
      <other_id>2010-021174-11</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>QUEST-2</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01290679</url>
  </study>
  <study rank="83">
    <nct_id>NCT01637532</nct_id>
    <title>Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Recurrent Ovarian Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tocilizumab and interferon alpha 2-b</intervention>
      <intervention type="Drug">Carboplatin and Caelyx or doxorubicin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Leiden University Medical Center</lead_sponsor>
      <collaborator>University Medical Center Groningen</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PITCH trial</other_id>
    </other_ids>
    <first_received>April 15, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 6, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PITCH</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The feasibility (NCI-CTCv4.0) to combine carboplatin and PLD or doxorubicin with tocilizumab as well as with tocilizumab and Peg-Intron</outcome_measure>
      <outcome_measure>The effect of chemo-immunotherapy on the immune system</outcome_measure>
      <outcome_measure>The relation between anti-tumor immunity and clinical outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01637532</url>
  </study>
  <study rank="84">
    <nct_id>NCT00049530</nct_id>
    <title>PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Melanoma (Skin)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eastern Cooperative Oncology Group</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000258114</other_id>
      <other_id>E2602</other_id>
      <other_id>U10CA021115</other_id>
    </other_ids>
    <first_received>November 12, 2002</first_received>
    <start_date>September 2003</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 6, 2015</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 30, 2014</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma b-FGF Level Response</outcome_measure>
      <outcome_measure>Non-progression Rate (Clinical Response to Peginterferon Alfa-2b)</outcome_measure>
      <outcome_measure>Progression Free Survival</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Michigan</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>West Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00049530</url>
  </study>
  <study rank="85">
    <nct_id>NCT00856024</nct_id>
    <title>ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>902</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05632</other_id>
      <other_id>BR 002-07</other_id>
    </other_ids>
    <first_received>March 4, 2009</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>October 14, 2011</firstreceived_results_date>
    <acronym>ATHENAS</acronym>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants Who Were Compliant to Treatment in the First 12 Weeks</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Early Virologic Response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00856024</url>
  </study>
  <study rank="86">
    <nct_id>NCT00686517</nct_id>
    <title>Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Biokos Farma srl</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03552</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2003</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>December 22, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period</outcome_measure>
      <outcome_measure>Virologic Response at the End of Treatment Follow-up (ETR)</outcome_measure>
      <outcome_measure>Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).</outcome_measure>
      <outcome_measure>Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Peripheral Blood Mononuclear Cells (PBMCs)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686517</url>
  </study>
  <study rank="87">
    <nct_id>NCT01366638</nct_id>
    <title>A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (pegIFN alfa-2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017935</other_id>
      <other_id>TMC435HPC3010</other_id>
    </other_ids>
    <first_received>June 2, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01366638</url>
  </study>
  <study rank="88">
    <nct_id>NCT00705432</nct_id>
    <title>Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1472</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05216</other_id>
      <other_id>EUDRACT # 2007-005508-42</other_id>
    </other_ids>
    <first_received>June 24, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <acronym>SPRINT-2</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705432</url>
  </study>
  <study rank="89">
    <nct_id>NCT01016912</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-021</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Weeks 4, 12, and 24</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01016912</url>
  </study>
  <study rank="90">
    <nct_id>NCT01502696</nct_id>
    <title>Adjuvant PEG Intron in Ulcerated Melanoma</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ulcerated Melanomas</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG IFN alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>European Organisation for Research and Treatment of Cancer - EORTC</lead_sponsor>
      <collaborator>NCIC Clinical Trials Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EORTC-18081</other_id>
      <other_id>2009-010273-20</other_id>
    </other_ids>
    <first_received>December 22, 2011</first_received>
    <start_date>October 2012</start_date>
    <last_updated>September 29, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relapse-free survival (RFS)</outcome_measure>
      <outcome_measure>Occurence of Adverse Events</outcome_measure>
      <outcome_measure>Overall survival (OS)</outcome_measure>
      <outcome_measure>Distant metastases-free survival (DMFS)</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01502696</url>
  </study>
  <study rank="91">
    <nct_id>NCT00323804</nct_id>
    <title>Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin-Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Rennes University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>372</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC15 NRfi</other_id>
      <other_id>2005-002937-11</other_id>
    </other_ids>
    <first_received>May 9, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 3, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.</outcome_measure>
      <outcome_measure>Distribution of the Metavir scoring on the end-of-study biopsy</outcome_measure>
      <outcome_measure>Distribution of the Chevallier fibrosis score</outcome_measure>
      <outcome_measure>Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies</outcome_measure>
      <outcome_measure>Fibrosis serum markers</outcome_measure>
      <outcome_measure>Liver elasticity before and after treatment</outcome_measure>
      <outcome_measure>Safety of treatment and quality of life</outcome_measure>
      <outcome_measure>Frequency of occurrence of hepatic complications and/or liver transplantations</outcome_measure>
      <outcome_measure>Evolution of the hepatitis C viral load</outcome_measure>
      <outcome_measure>Rate of patients with loss of detectable hepatitis C virus RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00323804</url>
  </study>
  <study rank="92">
    <nct_id>NCT00396019</nct_id>
    <title>Study of PEG-Intron for Plexiform Neurofibromas</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Plexiform Neurofibroma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital of Pittsburgh</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>87</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UPCI 06-116</other_id>
    </other_ids>
    <first_received>November 2, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>August 8, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcomes for the the study will be response or progression free survival, depending on the stratum in which the patient has enrolled.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00396019</url>
  </study>
  <study rank="93">
    <nct_id>NCT00502099</nct_id>
    <title>Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha 2 b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amr Hafez</lead_sponsor>
      <collaborator>Ain Shams University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>217</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LG161190-06</other_id>
    </other_ids>
    <first_received>July 15, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 21, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR, defined as undetectable serum HCV RNA</outcome_measure>
      <outcome_measure>histological response</outcome_measure>
      <outcome_measure>biochemical response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00502099</url>
  </study>
  <study rank="94">
    <nct_id>NCT00574730</nct_id>
    <title>CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-Hodgkins Lymphoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CHOP/Rituximab</intervention>
      <intervention type="Drug">PEG INTRON</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nebraska</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>013-01</other_id>
    </other_ids>
    <first_received>December 12, 2007</first_received>
    <start_date>May 2001</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>January 8, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Treatment Failure/Duration of Response/Time to Treatment Failure/Survival</outcome_measure>
      <outcome_measure>Biologic/Immunologic Evaluation on Study</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00574730</url>
  </study>
  <study rank="95">
    <nct_id>NCT01353911</nct_id>
    <title>Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo for Grazoprevir</intervention>
      <intervention type="Drug">Placebo for Boceprevir</intervention>
      <intervention type="Drug">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>368</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-003</other_id>
    </other_ids>
    <first_received>May 12, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving complete Early Viral Response (cEVR) in the Grazoprevir Treatment Arms</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events</outcome_measure>
      <outcome_measure>Number of participants discontinued from study due to adverse events</outcome_measure>
      <outcome_measure>Number of Participants Achieving Sustained Viral Response 24 weeks After the End of All Study Therapy (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01353911</url>
  </study>
  <study rank="96">
    <nct_id>NCT00423670</nct_id>
    <title>Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir (SCH 503034)</intervention>
      <intervention type="Drug">peginterferon-alfa 2b (PegIntron)</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin (low-dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>765</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03523</other_id>
      <other_id>EudraCT No. 2006-002543-92</other_id>
    </other_ids>
    <first_received>January 17, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>February 16, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on Duration of Boceprevir Treatment</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at FW 12</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at 72 Weeks Post Randomization</outcome_measure>
      <outcome_measure>Number of Participants With an Early Virologic Response (EVR) That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at Follow-up Week 12 That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at 72 Weeks Post Randomization That Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00423670</url>
  </study>
  <study rank="97">
    <nct_id>NCT00886457</nct_id>
    <title>5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Decitabine and Pegylated Interferon-Alfa 2B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nevada Cancer Institute</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NVCI-0725</other_id>
      <other_id>NCI 8224</other_id>
    </other_ids>
    <first_received>April 21, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>July 19, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Dose limiting toxicity based on CTCAE Version 3.0</outcome_measure>
      <outcome_measure>Genomic DNA methylation and Mage-1 specific promoter methylation in blood cells, tumor and skin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nevada</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00886457</url>
  </study>
  <study rank="98">
    <nct_id>NCT00759109</nct_id>
    <title>Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Carcinoma, Hepatocellular</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Other">Observation (no treatment)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02733</other_id>
    </other_ids>
    <first_received>August 26, 2008</first_received>
    <start_date>March 2002</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>June 8, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>March 24, 2011</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With the Development of Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Number of Participants With Development of Hepatic Decompensation</outcome_measure>
      <outcome_measure>Survival Time of Participants</outcome_measure>
      <outcome_measure>Number of Patients With a Virological Response Rate</outcome_measure>
      <outcome_measure>Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00759109</url>
  </study>
  <study rank="99">
    <nct_id>NCT02218164</nct_id>
    <title>Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Squamous Cell Carcinoma of Skin</condition>
      <condition>Carcinoma, Squamous Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alpha-2b</intervention>
      <intervention type="Drug">Capecitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCC-17759</other_id>
    </other_ids>
    <first_received>August 14, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>September 2017</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Objective Response Rate (ORR)</outcome_measure>
      <outcome_measure>Progression Free Survival (PFS)</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Occurence of Treatment Related Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02218164</url>
  </study>
  <study rank="100">
    <nct_id>NCT00423800</nct_id>
    <title>Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05016</other_id>
    </other_ids>
    <first_received>January 17, 2007</first_received>
    <start_date>December 2006</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>January 27, 2011</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With a Virological Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00423800</url>
  </study>
  <study rank="101">
    <nct_id>NCT01964300</nct_id>
    <title>Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Childhood Craniopharyngioma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pediatric Brain Tumor Consortium</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PBTC-039</other_id>
      <other_id>NCI-2013-01639</other_id>
      <other_id>U01CA081457</other_id>
    </other_ids>
    <first_received>October 14, 2013</first_received>
    <start_date>September 2013</start_date>
    <last_updated>April 27, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2100</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of disease stabilization for 1 year (i.e. 9 courses of treatment) (Stratum 1)</outcome_measure>
      <outcome_measure>Sustained objective response (PR+CR) rate in the cystic and/or soft tissue component observed during the first year of treatment (Stratum 2)</outcome_measure>
      <outcome_measure>Sustained objective response rate (Stratum 1)</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01964300</url>
  </study>
  <study rank="102">
    <nct_id>NCT01432535</nct_id>
    <title>Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Renal Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN-2b (Sylatron®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05655</other_id>
      <other_id>MK-4031-350</other_id>
    </other_ids>
    <first_received>September 9, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>July 23, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)</outcome_measure>
      <outcome_measure>AUC From Time 0 to the Last Measurable Sample (AUC0-last)</outcome_measure>
      <outcome_measure>Maximum Observed Serum Concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to Maximum Observed Serum Concentration (Tmax)</outcome_measure>
      <outcome_measure>Apparent Terminal Half-life (T1/2)</outcome_measure>
      <outcome_measure>Apparent Total Body Clearance (CL/F)</outcome_measure>
      <outcome_measure>Apparent Volume of Distribution (Vd/F)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01432535</url>
  </study>
  <study rank="103">
    <nct_id>NCT00351871</nct_id>
    <title>Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron Plus REBETOL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louisiana State University Health Sciences Center in New Orleans</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03851</other_id>
    </other_ids>
    <first_received>July 12, 2006</first_received>
    <start_date>April 2002</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>February 3, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in treatment response rates between those with insulin resistance those without.</outcome_measure>
      <outcome_measure>Which marker of Insulin Resistance (i.e. the HOMA score, Waste Circumference or BMI) is the best measure for risk of hypo responsiveness.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00351871</url>
  </study>
  <study rank="104">
    <nct_id>NCT00701298</nct_id>
    <title>Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">decitabine</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCI-2009-00295</other_id>
      <other_id>CDR0000597624</other_id>
      <other_id>NVCI-0725</other_id>
      <other_id>NVCI 07-25</other_id>
      <other_id>8224</other_id>
      <other_id>R21CA122270</other_id>
    </other_ids>
    <first_received>June 18, 2008</first_received>
    <start_date>April 2009</start_date>
    <last_updated>February 21, 2014</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Toxicities as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</outcome_measure>
      <outcome_measure>Dose-limiting toxicity (DLT) of pegylated interferon alfa-2b when given with decitabine as assessed by NCI CTCAE version 3.0</outcome_measure>
      <outcome_measure>Maximum-tolerated dose (MTD) of pegylated interferon alfa-2b when given with decitabine as assessed by NCI CTCAE version 3.0</outcome_measure>
      <outcome_measure>Global (genomic) DNA methylation changes by high-performance liquid chromatography (HPLC)</outcome_measure>
      <outcome_measure>Changes in expression of methylation-regulated genes in human biological tissues</outcome_measure>
      <outcome_measure>Complete and partial response rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nevada</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00701298</url>
  </study>
  <study rank="105">
    <nct_id>NCT00811967</nct_id>
    <title>Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03811</other_id>
      <other_id>JPC-02-320-34</other_id>
    </other_ids>
    <first_received>December 18, 2008</first_received>
    <start_date>February 2003</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response rate, defined as the proportion of subjects with undetectable HCV-RNA at 24-week post-treatment follow-up</outcome_measure>
      <outcome_measure>Rate of subject with undetectable HCV-RNA at the end of treatment (or at discontinuation of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00811967</url>
  </study>
  <study rank="106">
    <nct_id>NCT00797745</nct_id>
    <title>A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa 2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">SCH 900518</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05104</other_id>
    </other_ids>
    <first_received>November 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>January 21, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NEXT-1</acronym>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is the proportion of subjects with undetectable HCV-RNA after 4 weeks of treatment with SCH 900518.</outcome_measure>
      <outcome_measure>Rate of viral decline during the first 4 weeks of dosing with SCH 900518</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV-RNA at both 4 and 12 weeks of dosing with SCH 900518</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV-RNA at end of treatment (EOT) and follow-up week 24 (FW24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00797745</url>
  </study>
  <study rank="107">
    <nct_id>NCT01405560</nct_id>
    <title>Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Biological">peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-045</other_id>
    </other_ids>
    <first_received>July 28, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 6, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)24</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV Ribonucleic Acid (RNA) at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01405560</url>
  </study>
  <study rank="108">
    <nct_id>NCT00006325</nct_id>
    <title>Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>P1017</other_id>
      <other_id>PACTG P1017</other_id>
      <other_id>ACTG P1017</other_id>
      <other_id>11652</other_id>
    </other_ids>
    <first_received>October 2, 2000</first_received>
    <completion_date>March 2004</completion_date>
    <last_updated>May 18, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00006325</url>
  </study>
  <study rank="109">
    <nct_id>NCT00047879</nct_id>
    <title>Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Glioma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">Thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>030002</other_id>
      <other_id>03-C-0002</other_id>
    </other_ids>
    <first_received>June 19, 2006</first_received>
    <start_date>October 2002</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>September 19, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>May 24, 2011</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression-free Survival</outcome_measure>
      <outcome_measure>Number of Participants With Complete or Partial Response</outcome_measure>
      <outcome_measure>The Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00047879</url>
  </study>
  <study rank="110">
    <nct_id>NCT02112032</nct_id>
    <title>Treatment of Advanced Melanoma With MK-3475 and Peginterferon</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK-3475</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hassane M. Zarour, MD</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Melanoma Research Alliance</collaborator>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>13-105</other_id>
    </other_ids>
    <first_received>April 9, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 26, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Serious and Non-Serious Adverse Events</outcome_measure>
      <outcome_measure>Time to Disease Progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02112032</url>
  </study>
  <study rank="111">
    <nct_id>NCT01623336</nct_id>
    <title>BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
      <intervention type="Drug">Peginterferon alfa 2a 40kDA</intervention>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
      <collaborator>Hospital de Clinicas de Porto Alegre</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>740</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>11/0468</other_id>
    </other_ids>
    <first_received>June 13, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>June 15, 2012</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BIP48II/III</acronym>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.</outcome_measure>
      <outcome_measure>Frequency of adverse events</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01623336</url>
  </study>
  <study rank="112">
    <nct_id>NCT01425203</nct_id>
    <title>The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>238</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08160</other_id>
      <other_id>MK-3034-046</other_id>
    </other_ids>
    <first_received>August 26, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Participants Who Received At Least One Dose of Experimental Trial Drug (Modified Intent-To-Treat [mITT] Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Early Virologic Response (EVR) At Treatment Week (TW) 8</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01425203</url>
  </study>
  <study rank="113">
    <nct_id>NCT00511121</nct_id>
    <title>Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STI571 and PEG INTRON</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Bologna</lead_sponsor>
      <collaborator>Novartis</collaborator>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CML 011</other_id>
    </other_ids>
    <first_received>August 2, 2007</first_received>
    <start_date>April 2001</start_date>
    <last_updated>August 2, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>This is a study that is designed to determine the AE and the safety of a combination of standard dose of STI 571 (400 my daily) with a low-intermediate dose of *IFN (50 t0 150 ug weekly) and the compliane of the patients to the combination.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00511121</url>
  </study>
  <study rank="114">
    <nct_id>NCT00005012</nct_id>
    <title>Safety and Effectiveness of PEG-Intron in HIV-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Schering-Plough</lead_sponsor>
      <collaborator>NIH AIDS Clinical Trials Information Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>B010</other_id>
      <other_id>P00737</other_id>
    </other_ids>
    <first_received>March 29, 2000</first_received>
    <start_date>March 2000</start_date>
    <completion_date>September 2000</completion_date>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>August 2000</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00005012</url>
  </study>
  <study rank="115">
    <nct_id>NCT00863239</nct_id>
    <title>Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Locteron™ (controlled-release interferon alpha 2b)</intervention>
      <intervention type="Drug">PEG-Intron™</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>BLX883-203</other_id>
    </other_ids>
    <first_received>March 16, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SELECT-2</acronym>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>SVR: the proportion of subjects in each arm demonstrating HCV RNA undetectable (&lt; 10 IU/mL) at the end of the follow-up period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Bulgaria</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00863239</url>
  </study>
  <study rank="116">
    <nct_id>NCT01606800</nct_id>
    <title>Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>8908B-059</other_id>
    </other_ids>
    <first_received>May 24, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>START 4</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving Sustained Virologic Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01606800</url>
  </study>
  <study rank="117">
    <nct_id>NCT01636960</nct_id>
    <title>A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Malignant Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIFN alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08556</other_id>
      <other_id>MK-4031-370</other_id>
      <other_id>132228</other_id>
    </other_ids>
    <first_received>July 5, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>August 4, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase</outcome_measure>
      <outcome_measure>Safety: Number of Participants Experiencing Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing Study Drug Because of AEs</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01636960</url>
  </study>
  <study rank="118">
    <nct_id>NCT01701063</nct_id>
    <title>An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Janssen Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-118</other_id>
    </other_ids>
    <first_received>September 27, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>May 12, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety parameters, including AEs, study drug modifications or discontinuations, clinical laboratory values, vital signs, and electrocardiogram (ECG) assessments</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA at Week 4, at Week 12, at both Weeks 4 and 12 (eRVR), and at the planned end of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment virologic failure, defined as either meeting a futility rule or completing the assigned treatment duration with detectable HCV RNA at the EOT</outcome_measure>
      <outcome_measure>Proportion of subjects with virological relapse, defined as having undetectable HCV RNA at planned EOT followed by detectable HCV RNA after planned EOT</outcome_measure>
      <outcome_measure>Part A only, then Part B: Composite of Pharmacokinetics of telaprevir</outcome_measure>
      <outcome_measure>Changes from baseline in the amino acid sequence of the HCV NS3•4A protease</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01701063</url>
  </study>
  <study rank="119">
    <nct_id>NCT00134030</nct_id>
    <title>Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Localized Osteosarcoma</condition>
      <condition>Metastatic Osteosarcoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">doxorubicin hydrochloride</intervention>
      <intervention type="Drug">cisplatin</intervention>
      <intervention type="Drug">methotrexate</intervention>
      <intervention type="Procedure">therapeutic conventional surgery</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ifosfamide</intervention>
      <intervention type="Drug">etoposide</intervention>
      <intervention type="Procedure">quality-of-life assessment</intervention>
      <intervention type="Other">questionnaire administration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Oncology Group</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>University College London Hospitals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AOST0331</other_id>
      <other_id>NCI-2009-01066</other_id>
      <other_id>EUDRACT-2004-000242-20</other_id>
      <other_id>MRC-EURAMOS1</other_id>
      <other_id>MRC-BO08</other_id>
      <other_id>ISRCTN67613327</other_id>
      <other_id>EU-20530</other_id>
      <other_id>CDR0000438714</other_id>
      <other_id>COG-AOST0331</other_id>
      <other_id>U10CA098543</other_id>
    </other_ids>
    <first_received>August 22, 2005</first_received>
    <start_date>November 2005</start_date>
    <last_updated>August 20, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Event-free survival</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Toxicity as measured by CTCAE v3.0</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Delaware</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>Nevada</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>North Dakota</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>South Dakota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00134030</url>
  </study>
  <study rank="120">
    <nct_id>NCT00780416</nct_id>
    <title>Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>189</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A6</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780416</url>
  </study>
  <study rank="121">
    <nct_id>NCT00049842</nct_id>
    <title>Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02570</other_id>
    </other_ids>
    <first_received>November 14, 2002</first_received>
    <start_date>October 2002</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 7, 2010</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).</outcome_measure>
      <outcome_measure>Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)</outcome_measure>
      <outcome_measure>Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)</outcome_measure>
      <outcome_measure>The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the METAVIR Activity Score (Using a Continuous Scale)</outcome_measure>
      <outcome_measure>Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00049842</url>
  </study>
  <study rank="122">
    <nct_id>NCT00708500</nct_id>
    <title>Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (SCH 503034)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Drug">Boceprevir placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>404</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05101</other_id>
      <other_id>2007-005151-42</other_id>
    </other_ids>
    <first_received>June 27, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response.</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00708500</url>
  </study>
  <study rank="123">
    <nct_id>NCT00854581</nct_id>
    <title>Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lymphoma</condition>
      <condition>Precancerous/Nonmalignant Condition</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Biological">Interferon alfa-2b</intervention>
      <intervention type="Drug">Valproic Acid</intervention>
      <intervention type="Drug">Zidovudine</intervention>
      <intervention type="Genetic">Molecular Evaluation/Analysis of Malignant Clones of ATLL</intervention>
      <intervention type="Genetic">NF-kB Inhibition</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Miami</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>20070805</other_id>
      <other_id>SCCC-2007055</other_id>
    </other_ids>
    <first_received>February 28, 2009</first_received>
    <start_date>November 2007</start_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>December 22, 2014</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To Investigate Whether the Lack of IRF-4 and/or c-Rel is Associated With Response (CR or PR) to Zidovudine (AZT) and IFN Alpha-2b Therapy.</outcome_measure>
      <outcome_measure>Presence of Minimal Residual Disease at 3 and 6 Months of Maintained Remission and at 1 Year Post Initiation of Therapy</outcome_measure>
      <outcome_measure>To Analyze Clones From Patients Who Relapse to Determine Whether Antiviral Escape is Associated With Expression of IRF-4, c-Rel or Other Molecular Events (p53, p16 Mutations) Including Expansion of Novel Clones.</outcome_measure>
      <outcome_measure>To Investigate Whether AZT Functions as an Inhibitor of NF-kB in Vivo by Analyzing Serially Collected Leukemic Samples During the First 48 Hours of Treatment With AZT Only.</outcome_measure>
      <outcome_measure>Number of Patients Who Achieved Complete Response or Partial Response According to Molecular Response Criteria</outcome_measure>
      <outcome_measure>Failure-free Survival</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00854581</url>
  </study>
  <study rank="124">
    <nct_id>NCT00539591</nct_id>
    <title>Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Malignant Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Temozolomide</intervention>
      <intervention type="Drug">Recombinant interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St. Jude Children's Research Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEL06</other_id>
      <other_id>NCI-2011-01192</other_id>
    </other_ids>
    <first_received>October 2, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>September 2018</completion_date>
    <last_updated>August 4, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>September 10, 2013</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tumor Response Rate</outcome_measure>
      <outcome_measure>Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Strata B1 and B2</outcome_measure>
      <outcome_measure>Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Stratum A Patients</outcome_measure>
      <outcome_measure>Event-free Survival of Group A Participants</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00539591</url>
  </study>
  <study rank="125">
    <nct_id>NCT00528528</nct_id>
    <title>An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2b</intervention>
      <intervention type="Drug">Ribavirin (RBV) tablet</intervention>
      <intervention type="Drug">Ribavirin (RBV) capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>166</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013516</other_id>
      <other_id>VX-950-TIDP24-C208</other_id>
      <other_id>2007-001044-44</other_id>
    </other_ids>
    <first_received>September 10, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>June 13, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>March 18, 2013</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00528528</url>
  </study>
  <study rank="126">
    <nct_id>NCT00493805</nct_id>
    <title>Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04823</other_id>
      <other_id>EudraCT number:2006-000757-21</other_id>
    </other_ids>
    <first_received>June 25, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>October 27, 2010</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virological Response in Participants With and Without Insulin Resistance</outcome_measure>
      <outcome_measure>Sustained Virological Response (PCR 24 Weeks After End of Treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00493805</url>
  </study>
  <study rank="127">
    <nct_id>NCT02155322</nct_id>
    <title>A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Alfa-2b</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>4031-400</other_id>
    </other_ids>
    <first_received>June 2, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who experience an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants who discontinue study medication due to an AE</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02155322</url>
  </study>
  <study rank="128">
    <nct_id>NCT00299936</nct_id>
    <title>Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin, PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02314</other_id>
      <other_id>WIN-R</other_id>
    </other_ids>
    <first_received>March 3, 2006</first_received>
    <last_updated>March 3, 2006</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00299936</url>
  </study>
  <study rank="129">
    <nct_id>NCT00724061</nct_id>
    <title>Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lymphoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon α-2b</intervention>
      <intervention type="Other">Psoralens with ultraviolet light A</intervention>
      <intervention type="Other">Narrowband-ultraviolet light B</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NU 07H4</other_id>
      <other_id>P30CA060553</other_id>
      <other_id>SPRI-NU-07H4</other_id>
      <other_id>STU00002993</other_id>
    </other_ids>
    <first_received>July 26, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>November 25, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>November 25, 2013</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Dose Limiting Toxicities (DLTs) Observed During Dose Escalation of PEG-IFN-α-2b</outcome_measure>
      <outcome_measure>Change in Total Health-related Quality of Life Score Using the Functional Assessment of Cancer Therapy - Biologic Response Modifier (FACT-BRM)</outcome_measure>
      <outcome_measure>Number of Patients Exhibiting a Complete Response</outcome_measure>
      <outcome_measure>To Evaluate the Duration of Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00724061</url>
  </study>
  <study rank="130">
    <nct_id>NCT00630058</nct_id>
    <title>A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424(H), PEG-IFN-a-2b, RBV</intervention>
      <intervention type="Drug">MP-424 (L), PEG-IFN-a-2b, RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A5</other_id>
    </other_ids>
    <first_received>February 24, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>December 12, 2012</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>Tmax (Time of Maximum Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424</outcome_measure>
      <outcome_measure>Ctrough (Minimum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>T1/2(Time of Half-Life) of MP-424</outcome_measure>
      <outcome_measure>Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00630058</url>
  </study>
  <study rank="131">
    <nct_id>NCT02327416</nct_id>
    <title>A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Y peginterferon alfa-2b</intervention>
      <intervention type="Drug">Granulocyte-macrophage colony stimulating factor</intervention>
      <intervention type="Drug">Entecavir and or adefovir dipivoxil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
      <collaborator>Xiamen Amoytop Biotech Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Anchor study</other_id>
    </other_ids>
    <first_received>November 23, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>January 4, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of HBsAg loss at week 96</outcome_measure>
      <outcome_measure>Change from baseline in HBsAg quantification and HBsAg decline at week 96</outcome_measure>
      <outcome_measure>Change from baseline in HBsAg seroconversion at week 96</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02327416</url>
  </study>
  <study rank="132">
    <nct_id>NCT00686881</nct_id>
    <title>Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PegIFN-2b)</intervention>
      <intervention type="Drug">Comparator: Stronger neo minophagen C (SNMC)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>261</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04773</other_id>
      <other_id>JPC-05-356-30</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2006</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>February 3, 2012</firstreceived_results_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Change in Metavir Fibrosis Score</outcome_measure>
      <outcome_measure>Number of Participants With Alanine Aminotransferase (ALT) Normalization of &gt;16 Weeks Duration</outcome_measure>
      <outcome_measure>Number of Participants With Change in Metavir Inflammation Score</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686881</url>
  </study>
  <study rank="133">
    <nct_id>NCT01935089</nct_id>
    <title>Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alpha 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Wistar Institute</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Merck-0575</other_id>
    </other_ids>
    <first_received>August 27, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in copies of HIV DNA per CD4+ T cell at Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01935089</url>
  </study>
  <study rank="134">
    <nct_id>NCT00248339</nct_id>
    <title>Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon-alpha-2b (PEG-Intron)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Epoetin-alpha (Procrit)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
      <collaborator>Ortho Biotech, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1988 WIRB</other_id>
    </other_ids>
    <first_received>November 2, 2005</first_received>
    <start_date>May 2002</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>December 14, 2007</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The mean dose of ribavirin utilized in each of the 3 treatment arms will be compared.</outcome_measure>
      <outcome_measure>Number of patients in each group who required a dose reduction of ribavirin</outcome_measure>
      <outcome_measure>Rate of virologic response and sustained virologic response observed in each group</outcome_measure>
      <outcome_measure>Rate of decline in HCV RNA titer in each group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00248339</url>
  </study>
  <study rank="135">
    <nct_id>NCT00863109</nct_id>
    <title>Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Genotype 1</condition>
      <condition>HCV-1</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05278</other_id>
      <other_id>MK-4031-336</other_id>
    </other_ids>
    <first_received>March 12, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>May 14, 2014</firstreceived_results_date>
    <acronym>VIDA</acronym>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores</outcome_measure>
      <outcome_measure>Change From Baseline (BL) to Week 72 (WK72) in Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV)</outcome_measure>
      <outcome_measure>Change From Baseline to Week 72 (WK72) in SF-36 Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)</outcome_measure>
      <outcome_measure>Change From Baseline to Week 72 (WK72) in CLDQ-HCV Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)</outcome_measure>
      <outcome_measure>Minimal Clinically Important Difference (MCID) in SF-36 Scores</outcome_measure>
      <outcome_measure>MCID in CLDQ-HCV Scores</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Compliant With Treatment According To Medication Count (Subset Analysis)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00863109</url>
  </study>
  <study rank="136">
    <nct_id>NCT00279565</nct_id>
    <title>Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">buprenorphine</intervention>
      <intervention type="Drug">methadone</intervention>
      <intervention type="Drug">pegylated interferon alfa-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Reckitt Benckiser Pharmaceuticals Inc.</lead_sponsor>
      <collaborator>AESCA Pharma GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04279</other_id>
    </other_ids>
    <first_received>January 17, 2006</first_received>
    <start_date>August 2005</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>November 21, 2012</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00279565</url>
  </study>
  <study rank="137">
    <nct_id>NCT02099604</nct_id>
    <title>Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12226 ViZIR</other_id>
    </other_ids>
    <first_received>March 24, 2014</first_received>
    <start_date>April 2014</start_date>
    <last_updated>July 22, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ViZIR</acronym>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with Sustained Virological Response (SVR).</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Normalization of ALT during treatment and 12 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)</outcome_measure>
      <outcome_measure>Evolution of FibroScan values between pre-inclusion and week 60</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02099604</url>
  </study>
  <study rank="138">
    <nct_id>NCT01227356</nct_id>
    <title>A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Care Quality</condition>
      <condition>Health Care Evaluation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">imatinib and pegylated interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
      <collaborator>Uppsala University Hospital</collaborator>
      <collaborator>Karolinska University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NordCML002</other_id>
    </other_ids>
    <first_received>October 22, 2010</first_received>
    <start_date>September 2004</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>October 22, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of rate Major Molecular Response between treatment arms</outcome_measure>
      <outcome_measure>Comparison of complete cytogenetic response between the treatment arms at 12 months</outcome_measure>
      <outcome_measure>Comparison rate complete cytogenetic response between the treatment arms at 12 months</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01227356</url>
  </study>
  <study rank="139">
    <nct_id>NCT00045279</nct_id>
    <title>PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>01-143</other_id>
      <other_id>CDR0000256464</other_id>
      <other_id>NCI-G-02-2102</other_id>
    </other_ids>
    <first_received>September 6, 2002</first_received>
    <start_date>April 2002</start_date>
    <completion_date>September 2005</completion_date>
    <last_updated>June 4, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2005</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00045279</url>
  </study>
  <study rank="140">
    <nct_id>NCT00367887</nct_id>
    <title>A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
      <intervention type="Drug">HCV 796</intervention>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
      <intervention type="Drug">HCV 796</intervention>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
      <collaborator>ViroPharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3173A1-200</other_id>
      <other_id>B3381001</other_id>
    </other_ids>
    <first_received>August 21, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>February 7, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C Virus (HCV) RNA concentrations in the blood.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00367887</url>
  </study>
  <study rank="141">
    <nct_id>NCT00090870</nct_id>
    <title>PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Biological">sargramostim</intervention>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000378049</other_id>
      <other_id>MUSC-100614</other_id>
      <other_id>CELGENE-MUSC-100614</other_id>
      <other_id>MUSC-HR-10423</other_id>
    </other_ids>
    <first_received>September 7, 2004</first_received>
    <start_date>April 2002</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>April 26, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Toxicity</outcome_measure>
      <outcome_measure>Median and progression-free survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>South Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00090870</url>
  </study>
  <study rank="142">
    <nct_id>NCT00122629</nct_id>
    <title>Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg-interferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>405</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC03 BITRI</other_id>
    </other_ids>
    <first_received>July 20, 2005</first_received>
    <start_date>October 2000</start_date>
    <completion_date>May 2003</completion_date>
    <last_updated>July 28, 2005</last_updated>
    <last_verified>July 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation at week 72</outcome_measure>
      <outcome_measure>Biochemical response at week 72 defined as ALT normalization</outcome_measure>
      <outcome_measure>Histological benefit</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>Virological and biochemical responses during therapy at weeks 12, 24 and 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00122629</url>
  </study>
  <study rank="143">
    <nct_id>NCT02605252</nct_id>
    <title>New Strategy Study of Functional Cure of Chronic Hepatitis B</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3rd-sysu-hbv-functional cure</other_id>
    </other_ids>
    <first_received>November 8, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>November 11, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02605252</url>
  </study>
  <study rank="144">
    <nct_id>NCT00467077</nct_id>
    <title>Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">gefitinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>California Cancer Consortium</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000540598</other_id>
      <other_id>P30CA093373</other_id>
      <other_id>CCC-PHII-40</other_id>
      <other_id>ZENECA-AZ1839US/0227</other_id>
      <other_id>UCD-200412338-4</other_id>
      <other_id>UCD-ZD1839</other_id>
    </other_ids>
    <first_received>April 25, 2007</first_received>
    <start_date>September 2004</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>September 10, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression-free status at 6 months</outcome_measure>
      <outcome_measure>Response rate as measured by RECIST criteria</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Time to treatment failure</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00467077</url>
  </study>
  <study rank="145">
    <nct_id>NCT01405937</nct_id>
    <title>Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vaniprevir</intervention>
      <intervention type="Biological">peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-044</other_id>
    </other_ids>
    <first_received>July 28, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 3, 2014</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01405937</url>
  </study>
  <study rank="146">
    <nct_id>NCT01758588</nct_id>
    <title>Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myelofibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1202012178</other_id>
    </other_ids>
    <first_received>December 24, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>April 11, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evidence of improved clinical status</outcome_measure>
      <outcome_measure>Progression free survival and overall survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01758588</url>
  </study>
  <study rank="147">
    <nct_id>NCT00687219</nct_id>
    <title>Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05116</other_id>
      <other_id>JPC-06-320-35</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>June 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 18, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 27, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Week 24</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00687219</url>
  </study>
  <study rank="148">
    <nct_id>NCT00725842</nct_id>
    <title>Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peg-IFN alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05484</other_id>
    </other_ids>
    <first_received>July 28, 2008</first_received>
    <start_date>January 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 18, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>June 13, 2012</firstreceived_results_date>
    <acronym>RE-CHUT</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Positive Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) at 24 Weeks Off-treatment</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR), Early Virologic Response (EVR), or Slow Response Who Relapsed After Treatment</outcome_measure>
      <outcome_measure>Assessment of Pre-treatment Risk Factors of Relapse in Participants With Sustained Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With Positive HCV-RNA at 72 Weeks Off-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725842</url>
  </study>
  <study rank="149">
    <nct_id>NCT00363259</nct_id>
    <title>Pegintron Induction Therapy in HCV Non-Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV01-01</other_id>
    </other_ids>
    <first_received>August 10, 2006</first_received>
    <start_date>July 2002</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>August 10, 2006</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>sustained virological response (HCV-RNA negative 24 weeks after end of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00363259</url>
  </study>
  <study rank="150">
    <nct_id>NCT00522249</nct_id>
    <title>Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Carcinoma, Renal Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Alfa Interferon</intervention>
      <intervention type="Drug">sunitinib</intervention>
      <intervention type="Drug">erlotinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Methodist Hospital System</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RCC-06-101</other_id>
      <other_id>0806-0132</other_id>
    </other_ids>
    <first_received>August 27, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>August 21, 2008</last_updated>
    <last_verified>August 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to progression Objective response rate</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00522249</url>
  </study>
  <study rank="151">
    <nct_id>NCT00059358</nct_id>
    <title>Zidovudine Levels in HIV Infected Patients Being Treated for HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin plus interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01AI09141-01A1</other_id>
      <other_id>5R01AI049141-02</other_id>
    </other_ids>
    <first_received>April 23, 2003</first_received>
    <start_date>September 2001</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>August 6, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Steady state area under the concentration time curve (AUC) between 0 and 12 hours of zidovudine (ZDV)-MP, ZDV-TP, and dTTP in PBMCs from HIV and hepatitis C virus (HCV) coinfected patients before and after peginterferon alfa-2b with or without ribavirin</outcome_measure>
      <outcome_measure>Systemic exposure (AUC over 0 to 12 hours) of nelfinavir before and after peginterferon alfa-2b with or without ribavirin in HIV and HCV coinfected patients</outcome_measure>
      <outcome_measure>Effect of peginterferon alfa-2b with or without ribavirin in HCV RNA viral titers, alanine aminotransferase (ALT) levels, CD4+, and HIV-RNA viral titers in HIV and HCV coinfected patients</outcome_measure>
      <outcome_measure>Effect of peginterferon alfa-2b with or without ribavirin on liver histology</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00059358</url>
  </study>
  <study rank="152">
    <nct_id>NCT01195181</nct_id>
    <title>Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>Chronic Liver Disease</condition>
      <condition>Viral Hepatitis</condition>
      <condition>Therapeutic Uses</condition>
      <condition>Antiviral Agents</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera di Padova</lead_sponsor>
      <collaborator>Regione Veneto</collaborator>
      <collaborator>University of Padua</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>506</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPCOVE protocol</other_id>
      <other_id>DRG N.2920/2002</other_id>
    </other_ids>
    <first_received>August 31, 2010</first_received>
    <start_date>September 2005</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>September 3, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of real dose drugs intake in relation to sustained virological response (SVR).</outcome_measure>
      <outcome_measure>Description of the profile of the virus decay during antiviral therapy in relation to virological response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01195181</url>
  </study>
  <study rank="153">
    <nct_id>NCT00953589</nct_id>
    <title>480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BLX883-204</other_id>
    </other_ids>
    <first_received>August 5, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>480S</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary efficacy endpoint: EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>the proportion of subjects in each arm demonstrating HCV RNA undetectable (&lt; 10 IU/mL) after 12 weeks of randomized treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
      <country>Israel</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00953589</url>
  </study>
  <study rank="154">
    <nct_id>NCT00956982</nct_id>
    <title>PEG-IFN Plus Ribavirin Combination Therapy for Older Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyushu University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1251</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KULDS2009</other_id>
    </other_ids>
    <first_received>August 6, 2009</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>August 10, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>antiviral effect by PEG-IFN alpha-2b plus RBV treatment</outcome_measure>
      <outcome_measure>the tolerance of older patients by PEG-IFN alpha-2b plus RBV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00956982</url>
  </study>
  <study rank="155">
    <nct_id>NCT01678131</nct_id>
    <title>Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir 600 mg</intervention>
      <intervention type="Biological">Peg-IFN alfa-2b</intervention>
      <intervention type="Biological">Ribavirin</intervention>
      <intervention type="Procedure">Liver samples from FNA</intervention>
      <intervention type="Drug">Vaniprevir 300 mg</intervention>
      <intervention type="Procedure">Liver samples from CNB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-048</other_id>
      <other_id>2012-003284-21</other_id>
    </other_ids>
    <first_received>August 30, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants From Whom Detectable Concentrations of Hepatic Vaniprevir Are Obtained by FNA</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01678131</url>
  </study>
  <study rank="156">
    <nct_id>NCT00724451</nct_id>
    <title>Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05488</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Treatment by Reason for Discontinuation</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Failure by Reason for Failure</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724451</url>
  </study>
  <study rank="157">
    <nct_id>NCT01374308</nct_id>
    <title>NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">NASVAC</intervention>
      <intervention type="Drug">Pegylated interferon alpha 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Clinical Research Organization, Dhaka, Bangladesh</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NASVAC01</other_id>
    </other_ids>
    <first_received>June 12, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 11, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NASVAC</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of study participants with virological and or biochemical response as a measure of efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bangladesh</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01374308</url>
  </study>
  <study rank="158">
    <nct_id>NCT00623402</nct_id>
    <title>Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sorafenib</intervention>
      <intervention type="Drug">pegylated interferon α-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Schleswig-Holstein</lead_sponsor>
      <collaborator>Dermatologic Cooperative Oncology Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DeCOG SoraPeg 2007</other_id>
      <other_id>EudraCT 2007-001918-16</other_id>
    </other_ids>
    <first_received>February 1, 2008</first_received>
    <start_date>January 2008</start_date>
    <last_updated>January 11, 2011</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SoraPeg</acronym>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>disease control rate (CR,PR,SD)</outcome_measure>
      <outcome_measure>Best response</outcome_measure>
      <outcome_measure>Progression free survival (PFS)</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Safety and tolerability of the combined treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00623402</url>
  </study>
  <study rank="159">
    <nct_id>NCT01390844</nct_id>
    <title>Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Drug">Placebo to boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Cross-Over Boceprevir Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07063</other_id>
      <other_id>2007-005151-42</other_id>
      <other_id>3034-033</other_id>
      <other_id>CTRI/2012/04/002540</other_id>
    </other_ids>
    <first_received>July 7, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma hepatitis C virus ribonucleic acid (HCV-RNA) at Follow-up Week 24 in participants who received at least one dose of any trial medication (i.e. PEG, RBV, BOC, or placebo)</outcome_measure>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma HCV-RNA at Follow-up Week 24 in participants who received at least one dose of experimental trial medication (i.e. placebo or BOC)</outcome_measure>
      <outcome_measure>Number of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01390844</url>
  </study>
  <study rank="160">
    <nct_id>NCT00381017</nct_id>
    <title>Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Cirrhosis</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg interferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04371</other_id>
      <other_id>EUDRACT NUMBER:2005-003876-39</other_id>
    </other_ids>
    <first_received>September 26, 2006</first_received>
    <start_date>September 2006</start_date>
    <last_updated>August 11, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00381017</url>
  </study>
  <study rank="161">
    <nct_id>NCT01731301</nct_id>
    <title>A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Liver Institute of Virginia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Chronic Liver Disease Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIV01</other_id>
    </other_ids>
    <first_received>November 16, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 20, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who achieve eRVR at treatment week 28</outcome_measure>
      <outcome_measure>Tolerability of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01731301</url>
  </study>
  <study rank="162">
    <nct_id>NCT00686777</nct_id>
    <title>Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05172</other_id>
      <other_id>JPC-06-320-40</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>December 12, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686777</url>
  </study>
  <study rank="163">
    <nct_id>NCT02358044</nct_id>
    <title>Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Biological">PegIntron</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Grazoprevir/Elbasvir (100 mg/50 mg) FDC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>257</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-077</other_id>
      <other_id>2014-003836-38</other_id>
    </other_ids>
    <first_received>February 3, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing at least 1 adverse event (AE) on study</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 24 weeks after ending study treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 4 weeks after ending study treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing a Tier 1 safety event (parameter/AE of special interest identified a priori in protocol subject to inferential testing for statistical significance)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02358044</url>
  </study>
  <study rank="164">
    <nct_id>NCT01710501</nct_id>
    <title>A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C (CHC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>87</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-038</other_id>
      <other_id>2012-003333-42</other_id>
    </other_ids>
    <first_received>October 17, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects achieving Sustained Virologic Response (SVR) at 12 weeks (SVR12) after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants experiencing at least one adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants discontinued from study treatment due to AEs</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable hepatitis C virus ribonucleic acid (HCV RNA) at Week 2</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 24</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 24</outcome_measure>
      <outcome_measure>Number of subjects achieving SVR4</outcome_measure>
      <outcome_measure>Number of subjects achieving SVR24</outcome_measure>
      <outcome_measure>Number of participants who develop antiviral resistance to grazoprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01710501</url>
  </study>
  <study rank="165">
    <nct_id>NCT01243281</nct_id>
    <title>Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN and entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chulalongkorn University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>Biochem2010/01</other_id>
    </other_ids>
    <first_received>November 17, 2010</first_received>
    <start_date>March 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>June 26, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine whether a combination of PEG-IFN and entecavir improves the rate of sustained response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B</outcome_measure>
      <outcome_measure>To determine host factors and viral factors associated with response to PEG-IFN alone or PEG-IFN plus entecavir treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01243281</url>
  </study>
  <study rank="166">
    <nct_id>NCT02001818</nct_id>
    <title>Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukaemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nilotinib, Pegylated interferon alpha-2b, Imatinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Australasian Leukaemia and Lymphoma Group</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme (Australia) Pty Limited</collaborator>
      <collaborator>Novartis Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CML11</other_id>
      <other_id>ACTRN12612000851864</other_id>
    </other_ids>
    <first_received>November 12, 2013</first_received>
    <start_date>April 2014</start_date>
    <completion_date>December 2021</completion_date>
    <last_updated>May 18, 2014</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PInNACLe</acronym>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>level of BCR-ABL</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02001818</url>
  </study>
  <study rank="167">
    <nct_id>NCT02379195</nct_id>
    <title>Peginterferon and TIL Therapy for Metastatic Melanoma</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metastatic Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclophosphamide</intervention>
      <intervention type="Drug">Fludarabine</intervention>
      <intervention type="Biological">TIL infusion</intervention>
      <intervention type="Drug">Interleukin-2</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Inge Marie Svane</lead_sponsor>
      <collaborator>Herlev Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MM1413</other_id>
    </other_ids>
    <first_received>February 27, 2015</first_received>
    <start_date>November 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>August 17, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number and type of reported adverse events</outcome_measure>
      <outcome_measure>Treatment related immune responses</outcome_measure>
      <outcome_measure>Objective response rate</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Progression free survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02379195</url>
  </study>
  <study rank="168">
    <nct_id>NCT00036569</nct_id>
    <title>A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diffuse Intrinsic Pontine Glioma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">adjuvant therapy</intervention>
      <intervention type="Biological">pegylated interferon alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>020193</other_id>
      <other_id>02-C-0193</other_id>
    </other_ids>
    <first_received>May 10, 2002</first_received>
    <start_date>May 2002</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>January 10, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>September 20, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas</outcome_measure>
      <outcome_measure>Median Time to Progression</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Mean Quality of Life (QOL) Score at Baseline and Follow-Up</outcome_measure>
      <outcome_measure>Number of Participants With a Metabolic and Biological Change in the Brainstem Through Magnetic Resonance Imaging (MRI) Techniques</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00036569</url>
  </study>
  <study rank="169">
    <nct_id>NCT00215865</nct_id>
    <title>PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGIntron plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepatitis Resource Network</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRN 003</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <last_updated>September 20, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>1. To compare the Sustained Virologic Response (SVR) of PEGIntron plus ribavirin among patients receiving a fixed dose of PEGIntron versus weighted-adjusted dosing</outcome_measure>
      <outcome_measure>2. To evaluate the safety and tolerability PEG Intron in combination with ribavirin given as a fixed dose versus weight adjusted.</outcome_measure>
      <outcome_measure>3. To determine the Early Virologic Response (EVR) at week 24.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00215865</url>
  </study>
  <study rank="170">
    <nct_id>NCT01025765</nct_id>
    <title>The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Acarbose</intervention>
      <intervention type="Drug">Metformin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200905056M</other_id>
    </other_ids>
    <first_received>December 2, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>November 23, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>serum ALT normalization, and histologic improvement</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01025765</url>
  </study>
  <study rank="171">
    <nct_id>NCT01986712</nct_id>
    <title>An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Sanjiv Agarwala, MD</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>St. Luke's Hospital and Health Network, Pennsylvania</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Merck MISP 50422</other_id>
    </other_ids>
    <first_received>October 23, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate Compliance with Standard High Dose Interferon (HDI) versus Sylatron</outcome_measure>
      <outcome_measure>Compare Quality of Life (Qol)for patients on HDI versus PEG IFN</outcome_measure>
      <outcome_measure>Assess the frequency of Grade 3 and Grade 4 Toxicities</outcome_measure>
      <outcome_measure>Examine the Reasons for Patients' Choice of Treatment with HDI versus PEG IFN</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01986712</url>
  </study>
  <study rank="172">
    <nct_id>NCT01872442</nct_id>
    <title>Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Phase of Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dasatinib</intervention>
      <intervention type="Drug">Peg-Interferon alpha2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Poitiers University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>DASA-PegIFN</other_id>
    </other_ids>
    <first_received>May 14, 2013</first_received>
    <start_date>October 2013</start_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cumulative rate of molecular response</outcome_measure>
      <outcome_measure>Rate of complete cytogenetic response</outcome_measure>
      <outcome_measure>Rate of major molecular responses</outcome_measure>
      <outcome_measure>Rate of molecular response</outcome_measure>
      <outcome_measure>Kinetics and duration</outcome_measure>
      <outcome_measure>Rate of PegIFN-α2b and dasatinib discontinuation</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01872442</url>
  </study>
  <study rank="173">
    <nct_id>NCT00087607</nct_id>
    <title>PEAK Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">PEG-Intron</intervention>
      <intervention type="Drug">Rebetol</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>385</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17756</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral load reduction from baseline.</outcome_measure>
      <outcome_measure>Viral load reduction</outcome_measure>
      <outcome_measure>Viral AUC and AAUCMB.</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>Nevada</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087607</url>
  </study>
  <study rank="174">
    <nct_id>NCT00725751</nct_id>
    <title>Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon alfa-2b (PegIFN-2b)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05255</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>September 2007</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 23, 2012</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants Who Received Antiviral Treatment Who Were Also on Substitution Therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725751</url>
  </study>
  <study rank="175">
    <nct_id>NCT00015652</nct_id>
    <title>Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Aldesleukin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5088</other_id>
      <other_id>AACTG A5088</other_id>
      <other_id>10676</other_id>
      <other_id>ACTG A5088</other_id>
    </other_ids>
    <first_received>April 26, 2001</first_received>
    <completion_date>March 2005</completion_date>
    <last_updated>May 21, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00015652</url>
  </study>
  <study rank="176">
    <nct_id>NCT01653236</nct_id>
    <title>Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Genotype 4 Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Theodor Bilharz Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-108</other_id>
    </other_ids>
    <first_received>July 26, 2012</first_received>
    <start_date>December 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 25, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Week 8 Response</outcome_measure>
      <outcome_measure>12 Weeks response</outcome_measure>
      <outcome_measure>IL-28B polymorphism</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01653236</url>
  </study>
  <study rank="177">
    <nct_id>NCT00351403</nct_id>
    <title>Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FGK Clinical Research GmbH</lead_sponsor>
      <collaborator>University Hospital, Saarland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>INDIV-2</other_id>
      <other_id>2006-000358-38</other_id>
    </other_ids>
    <first_received>July 11, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>February 5, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (HCV RNA negativity 24 weeks after end of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00351403</url>
  </study>
  <study rank="178">
    <nct_id>NCT01639885</nct_id>
    <title>Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Recurrent Ovarian Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Alfa-2b</intervention>
      <intervention type="Drug">Interferon Alfa-2b</intervention>
      <intervention type="Biological">p53 SLP</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Leiden University Medical Center</lead_sponsor>
      <collaborator>University Medical Center Groningen</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHIP trial</other_id>
      <other_id>2010-023124-24</other_id>
    </other_ids>
    <first_received>April 16, 2012</first_received>
    <start_date>August 2011</start_date>
    <last_updated>January 6, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CHIP</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Feasibility (change in grade III and IV toxicity) and change in immunogenicity of the triple combination of gemcitabine, Peg-Intron and p53 SLP vaccination</outcome_measure>
      <outcome_measure>Clinical outcome (response (RECIST 1.1)</outcome_measure>
      <outcome_measure>The effect of this new treatment combination on the immune system</outcome_measure>
      <outcome_measure>progression free survival</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01639885</url>
  </study>
  <study rank="179">
    <nct_id>NCT01466192</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A10</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01466192</url>
  </study>
  <study rank="180">
    <nct_id>NCT01468584</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A11</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01468584</url>
  </study>
  <study rank="181">
    <nct_id>NCT00780910</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A8</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780910</url>
  </study>
  <study rank="182">
    <nct_id>NCT00781274</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A9</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00781274</url>
  </study>
  <study rank="183">
    <nct_id>NCT00087646</nct_id>
    <title>REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>948</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV17150</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>September 2003</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response rate</outcome_measure>
      <outcome_measure>Percentage of patients with &gt;=2log drop in HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Portugal</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087646</url>
  </study>
  <study rank="184">
    <nct_id>NCT00332176</nct_id>
    <title>A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
      <intervention type="Drug">Celgosivir</intervention>
      <intervention type="Drug">Peginterferon alfa 2b + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-06-001</other_id>
    </other_ids>
    <first_received>May 30, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>April 3, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Pharmacokinetics of celgosivir/castanospermine</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00332176</url>
  </study>
  <study rank="185">
    <nct_id>NCT01482767</nct_id>
    <title>Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Interferon Alfa 2b (PEG-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>262</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5294 (BIRTH)</other_id>
      <other_id>11774</other_id>
      <other_id>ACTG 5294</other_id>
      <other_id>BIRTH</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>April 2012</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 3 or higher signs and symptoms and laboratory abnormalities and other serious adverse events (AEs) during the study</outcome_measure>
      <outcome_measure>Undetectable HCV RNA discontinuation (SVR12)</outcome_measure>
      <outcome_measure>Baseline HIV-1 viral load and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline CD4+ T-cell count and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline fibrosis stage, race, gender, insulin sensitivity, and HCV viral load level</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 2 or higher signs and symptoms and laboratory abnormalities and other serious AEs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482767</url>
  </study>
  <study rank="186">
    <nct_id>NCT02332473</nct_id>
    <title>A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Granulocyte-macrophage colony stimulating factor</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University First Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1405IFN</other_id>
    </other_ids>
    <first_received>January 4, 2015</first_received>
    <start_date>June 2014</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>July 21, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of HBeAg seroconversion at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of HBsAg undetectable and seroconversion at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg undetectable and seroconversion at week 12, 24, 36 and 48</outcome_measure>
      <outcome_measure>Change of HBsAg and HBeAg from baseline at week 12, 24, 36, and 48</outcome_measure>
      <outcome_measure>Change of HBV DNA from baseline and percentage of HBV DNA undetectable at week 12, 24, 36, and 48</outcome_measure>
      <outcome_measure>Percentage of ALT normalization at week 24, 36 and 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02332473</url>
  </study>
  <study rank="187">
    <nct_id>NCT01727271</nct_id>
    <title>A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenofovir</intervention>
      <intervention type="Biological">Pegylated interferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>4031-384</other_id>
    </other_ids>
    <first_received>November 12, 2012</first_received>
    <start_date>August 2013</start_date>
    <completion_date>August 2017</completion_date>
    <last_updated>September 18, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who responded to treatment</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to AEs</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01727271</url>
  </study>
  <study rank="188">
    <nct_id>NCT01335529</nct_id>
    <title>Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>HIV-1 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir, Peg-interferon alfa 2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Rennes University Hospital</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC27 BOCEPREVIH</other_id>
    </other_ids>
    <first_received>March 25, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 10, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BocepreVIH</acronym>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Predictive factors of Sustained virologic Response (SVR)</outcome_measure>
      <outcome_measure>HIV virologic endpoints</outcome_measure>
      <outcome_measure>Residual plasmatic concentration (Cres) of Ribavirin</outcome_measure>
      <outcome_measure>Hepatic factors: liver fibrosis score</outcome_measure>
      <outcome_measure>Alcohol consumption</outcome_measure>
      <outcome_measure>Evaluation of Pharmacokinetic parameters of anti-retroviral treatments</outcome_measure>
      <outcome_measure>Clinical and biological adverse events</outcome_measure>
      <outcome_measure>Number of participants classified by virologic failure type: non responder, relapser, null responder</outcome_measure>
      <outcome_measure>ITPA gene polymorphism</outcome_measure>
      <outcome_measure>CYP3A4 Polymorphism</outcome_measure>
      <outcome_measure>Maximal Concentration (Cmax) of antiretroviral treatments</outcome_measure>
      <outcome_measure>Area Under the Curve (AUC) of antiretrovirals</outcome_measure>
      <outcome_measure>Insulin resistance</outcome_measure>
      <outcome_measure>Metabolic syndrome</outcome_measure>
      <outcome_measure>Reasons and dates of treatment discontinuation</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>French AIDS questionnaire of compliance</outcome_measure>
      <outcome_measure>Tobacco consumption</outcome_measure>
      <outcome_measure>Cannabis consumption</outcome_measure>
      <outcome_measure>Intravenous/nasal drugs consumption</outcome_measure>
      <outcome_measure>Residual Concentration (Cres) of atazanavir boosted or not by ritonavir</outcome_measure>
      <outcome_measure>Residual concentration (Cres) of ritonavir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01335529</url>
  </study>
  <study rank="189">
    <nct_id>NCT00910624</nct_id>
    <title>Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05514</other_id>
    </other_ids>
    <first_received>May 28, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>September 18, 2013</firstreceived_results_date>
    <acronym>PROVIDE</acronym>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) Leading to Dose Modification (DM) or Discontinuation (DC), Treatment-Related Serious AEs (SAEs), Neutrophil Count &lt;0.75 × 10^9/L, or Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00910624</url>
  </study>
  <study rank="190">
    <nct_id>NCT00087568</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16965</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2002</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients able to complete prescribed length of Pegasys plus ribavirin therapy\n</outcome_measure>
      <outcome_measure>Sum score of Beck Depression Inventory and Fatigue Severity Score, proportion of patients with each flu-like symptom, &gt;=2 log drop or undetectable HCV-RNA, or normal ALT levels, adverse events, laboratory values\n</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087568</url>
  </study>
  <study rank="191">
    <nct_id>NCT00573378</nct_id>
    <title>Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN-a2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCC 2006.128</other_id>
      <other_id>HUM9600</other_id>
    </other_ids>
    <first_received>December 13, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>May 18, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relapse-free survival (RFS) rate 1 year after discontinuation of the TKI and IFN</outcome_measure>
      <outcome_measure>Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) for the Bcr-Abl transcript.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00573378</url>
  </study>
  <study rank="192">
    <nct_id>NCT00871533</nct_id>
    <title>Pilot Study of IFN α2b for Melanoma Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IFNα2b</intervention>
      <intervention type="Drug">IFNα2b</intervention>
      <intervention type="Drug">PEG- IFNα2b</intervention>
      <intervention type="Drug">PEG- IFNα2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-067</other_id>
    </other_ids>
    <first_received>March 26, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To utilize gene-profiling analysis of regional lymph node tissue to molecularly characterize the effect of IFN α2b and PEG IFNα2b on the SLN. Endpoint: mRNA expression by gene array.</outcome_measure>
      <outcome_measure>Quantitate putative biomarkers differentially expressed in the SLN for each active treatment group and among all active treatment groups combined. Endpoint: mRNA expression by Taqman.</outcome_measure>
      <outcome_measure>Molecularly characterize the effect of perilesional IFN α2b and PEG IFNα2b administered as close as possible to the primary tumor site on SLNs that are positive vs. negative for tumor micrometastases. Endpoint: mRNA expression by gene array.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00871533</url>
  </study>
  <study rank="193">
    <nct_id>NCT00446134</nct_id>
    <title>Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-204</other_id>
    </other_ids>
    <first_received>March 8, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>June 20, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>September 20, 2011</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patients With Either Undetectable Serum HCV RNA (&lt;100 Copies/ml) or at Least a 2-log Decrease From Baseline in Serum Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Treatment Week 12.</outcome_measure>
      <outcome_measure>Patients With Anemia (Hemoglobin &lt;10 g/dL) Up to Follow-up Week 24</outcome_measure>
      <outcome_measure>Patients With Undetected Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) (&lt;100 Copies/mL) at Treatment Week Follow-Up 24</outcome_measure>
      <outcome_measure>Relapsers at Follow-Up Visit 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00446134</url>
  </study>
  <study rank="194">
    <nct_id>NCT01370642</nct_id>
    <title>Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vaniprevir</intervention>
      <intervention type="Drug">Placebo to vaniprevir</intervention>
      <intervention type="Biological">Peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-043</other_id>
    </other_ids>
    <first_received>June 8, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Tier 1 Adverse Events (AEs) During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Least Squares (LS) Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01370642</url>
  </study>
  <study rank="195">
    <nct_id>NCT00277862</nct_id>
    <title>Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated IFN- alpha 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Fulbright</collaborator>
      <collaborator>TEMPUS</collaborator>
      <collaborator>International Society for Infectious Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>G43230832638</other_id>
    </other_ids>
    <first_received>January 15, 2006</first_received>
    <start_date>April 2002</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>February 25, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic response defined as undetectable serum HCV RNA levels (Amplicor HCV, Roche Molecular Systems; lower limit of detection (LLD) of 50 IU/mL)</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment (EOT) defined as undetectable HCV RNA serum levels (50 IU/ml) at the end of the scheduled treatment period</outcome_measure>
      <outcome_measure>sustained virologic response (primary) histological response (secondary) biochemical response (secondary)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00277862</url>
  </study>
  <study rank="196">
    <nct_id>NCT01871662</nct_id>
    <title>Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Legalon® SIL (Silibinin)</intervention>
      <intervention type="Drug">Pegylated interferon alfa2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rottapharm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LEG-SIL-2-02</other_id>
    </other_ids>
    <first_received>May 30, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEPASIL</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment</outcome_measure>
      <outcome_measure>Undetectable HCV-RNA</outcome_measure>
      <outcome_measure>HCV-RNA decrease ≥ 2 log10 IU/mL</outcome_measure>
      <outcome_measure>Normalization of Serum Alanine Aminotransferase</outcome_measure>
      <outcome_measure>Number of Participants with adverse events (AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01871662</url>
  </study>
  <study rank="197">
    <nct_id>NCT00253474</nct_id>
    <title>PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neoplasm of Uncertain Malignant Potential</condition>
      <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>050232</other_id>
      <other_id>05-C-0232</other_id>
      <other_id>NCI-P6670</other_id>
      <other_id>CDR0000448811</other_id>
    </other_ids>
    <first_received>November 11, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>March 28, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00253474</url>
  </study>
  <study rank="198">
    <nct_id>NCT00238329</nct_id>
    <title>PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Intraocular Melanoma</condition>
      <condition>Melanoma (Skin)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Barbara Ann Karmanos Cancer Institute</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000445593</other_id>
      <other_id>P30CA022453</other_id>
      <other_id>WSU-C-2257</other_id>
      <other_id>WSU-HIC-120900M01-FB</other_id>
    </other_ids>
    <first_received>October 12, 2005</first_received>
    <start_date>January 2001</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>April 5, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response rate as measured scans and tumor measurements every 8 weeks</outcome_measure>
      <outcome_measure>Qualitative and quantitative toxicities at 30 days following study treatment</outcome_measure>
      <outcome_measure>Progression-free survival by standard life table and Kaplan-Meier</outcome_measure>
      <outcome_measure>Overall survival by standard life table and Kaplan-Meier</outcome_measure>
      <outcome_measure>Vascular flow to metastatic sites by positron-emission tomography scan every 8 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00238329</url>
  </study>
  <study rank="199">
    <nct_id>NCT00919633</nct_id>
    <title>Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin, USP</intervention>
      <intervention type="Device">external drug infusion pump</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medtronic Corporate Technologies and New Ventures</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>4316001</other_id>
    </other_ids>
    <first_received>June 10, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>March 28, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>March 28, 2014</firstreceived_results_date>
    <acronym>COPE-HCV</acronym>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral Load: Incidence of Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Safety/Tolerability</outcome_measure>
      <outcome_measure>Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>End-of-treatment Response (EOT)</outcome_measure>
      <outcome_measure>Pharmacokinetics</outcome_measure>
      <outcome_measure>Pharmacodynamics</outcome_measure>
      <outcome_measure>Functional Health, Depression Score, and Fatigue Level</outcome_measure>
      <outcome_measure>Viral Decay</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00919633</url>
  </study>
  <study rank="200">
    <nct_id>NCT00310336</nct_id>
    <title>Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">S-adenosyl-L-methionine</intervention>
      <intervention type="Drug">betaine</intervention>
      <intervention type="Drug">pegylated interferon alpha2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EKBB 37/06</other_id>
    </other_ids>
    <first_received>March 31, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>October 27, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained response rate</outcome_measure>
      <outcome_measure>Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00310336</url>
  </study>
  <study rank="201">
    <nct_id>NCT01440595</nct_id>
    <title>Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012 AM1)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Placebo to Grazoprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-012</other_id>
    </other_ids>
    <first_received>September 22, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>November 9, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants achieving complete early virologic response (cEVR) in the grazoprevir treatment arms</outcome_measure>
      <outcome_measure>Time to first achievement of undetectable HCV ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Number of participants achieving rapid viral response (RVR)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained viral response 12 weeks after completion of therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained viral response 24 weeks after completion of therapy (SVR24)</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 12 in the Placebo arm</outcome_measure>
      <outcome_measure>Number of participants achieving complete early virologic response (cEVR) at Week 24 in the Placebo arm</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01440595</url>
  </study>
  <study rank="202">
    <nct_id>NCT00148837</nct_id>
    <title>Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2b (drug)</intervention>
      <intervention type="Drug">Ribavirin (drug)</intervention>
      <intervention type="Drug">Prazosin (drug)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-001326-24</other_id>
      <other_id>ANRSHC17 Prazor</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>September 2004</start_date>
    <last_updated>February 6, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients presenting a decrease of fibrosis as measured on the liver biopsy and considered as clinically interesting (decrease of fibrosis pre- and post-therapeutic (W96) measures of at least 10 percent)</outcome_measure>
      <outcome_measure>Metavir scoring system; immunostaining of alpha-smooth muscle actin; indirect markers of fibrosis (Fibrotest) at W96</outcome_measure>
      <outcome_measure>Sustained virological response: undetectable HCV RNA at W96</outcome_measure>
      <outcome_measure>Sustained biochemical response: ALT level at W96</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00148837</url>
  </study>
  <study rank="203">
    <nct_id>NCT00014261</nct_id>
    <title>Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">temozolomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dartmouth-Hitchcock Medical Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000068523</other_id>
      <other_id>P30CA023108</other_id>
      <other_id>DMS-0010</other_id>
      <other_id>NCI-G01-1924</other_id>
    </other_ids>
    <first_received>April 10, 2001</first_received>
    <start_date>October 2000</start_date>
    <last_updated>March 15, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2002</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Hampshire</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00014261</url>
  </study>
  <study rank="204">
    <nct_id>NCT02168361</nct_id>
    <title>The SIM-SOF Trial for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Center For Hepatitis C, Atlanta, GA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHC-21</other_id>
    </other_ids>
    <first_received>June 17, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>June 19, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 (SVR-12)</outcome_measure>
      <outcome_measure>Virologic Relapse</outcome_measure>
      <outcome_measure>Virologic Breakthrough</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02168361</url>
  </study>
  <study rank="205">
    <nct_id>NCT00689390</nct_id>
    <title>Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Boceprevir</intervention>
      <intervention type="Biological">Narlaprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Blood/Plasma Collection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1954</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05063</other_id>
      <other_id>2006-006529-25</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 1, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response)</outcome_measure>
      <outcome_measure>Kaplan-Meier Exposure-adjusted Relapse Rate</outcome_measure>
      <outcome_measure>Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU</outcome_measure>
      <outcome_measure>Number of Participants That Discontinued the LTFU Due to SAEs</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00689390</url>
  </study>
  <study rank="206">
    <nct_id>NCT00117533</nct_id>
    <title>Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
      <condition>Chronic Hepatitis D</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated IFN alfa-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Health Research Institutes, Taiwan</collaborator>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>930904</other_id>
    </other_ids>
    <first_received>June 30, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>May 24, 2006</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B</outcome_measure>
      <outcome_measure>the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate</outcome_measure>
      <outcome_measure>The degree of histologic change</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00117533</url>
  </study>
  <study rank="207">
    <nct_id>NCT00585221</nct_id>
    <title>Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gastrointestinal Stromal Tumors,</condition>
      <condition>Cancer,</condition>
      <condition>Solid Tumors</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon-alpha 2b (PegIFNa2b);</intervention>
      <intervention type="Drug">Imatinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Utah</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB_00022172</other_id>
    </other_ids>
    <first_received>December 21, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>July 23, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>June 15, 2012</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Decrease in Tumor Size.</outcome_measure>
      <outcome_measure>Time to Progression (TTP).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00585221</url>
  </study>
  <study rank="208">
    <nct_id>NCT02227277</nct_id>
    <title>Reducing Proviral HIV DNA With Interferon-a</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>HIV/AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFN-α2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Wistar Institute</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ES11990</other_id>
      <other_id>1U01AI110434</other_id>
    </other_ids>
    <first_received>August 25, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BEAT-HIV</acronym>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Integrated HIV proviral DNA</outcome_measure>
      <outcome_measure>Integrated proviral DNA in tissue</outcome_measure>
      <outcome_measure>CD4 count</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02227277</url>
  </study>
  <study rank="209">
    <nct_id>NCT00135798</nct_id>
    <title>Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LADR Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Ortho Biotech Clinical Affairs, L.L.C.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A2ALL LADR Protocol 62498(IND)</other_id>
      <other_id>U01DK062498</other_id>
      <other_id>U01DK062536</other_id>
      <other_id>U01DK062444</other_id>
      <other_id>U01DK062467</other_id>
      <other_id>U01DK062483</other_id>
      <other_id>U01DK062484</other_id>
      <other_id>U01DK062494</other_id>
      <other_id>U01DK062496</other_id>
      <other_id>U01DK062505</other_id>
      <other_id>U01DK062531</other_id>
      <other_id>CRADA through NIH-NIDDK</other_id>
      <other_id>CTA through NIH-NIDDK</other_id>
      <other_id>HRSA</other_id>
      <other_id>ASTS</other_id>
    </other_ids>
    <first_received>August 24, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>April 11, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>June 13, 2012</firstreceived_results_date>
    <acronym>LADR</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT)</outcome_measure>
      <outcome_measure>Patients Who Are Negative for HCV RNA at 3 Months Post-transplant: Per-Protocol Analysis (PP)</outcome_measure>
      <outcome_measure>Patients With Combined Virologic Response (CVR): Intent-to-Treat Analyses (ITT)</outcome_measure>
      <outcome_measure>Patients With Combined Virologic Response (CVR): Per-Protocol Analysis (PP)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00135798</url>
  </study>
  <study rank="210">
    <nct_id>NCT01756079</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-105</other_id>
      <other_id>2012-002772-13</other_id>
    </other_ids>
    <first_received>December 19, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 29, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who achieve sustained viral response (SVR) at 24 weeks after the end of all study treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01756079</url>
  </study>
  <study rank="211">
    <nct_id>NCT00724893</nct_id>
    <title>Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2430</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04423</other_id>
      <other_id>MK-4031-267</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>August 2005</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 29, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Viral Load (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype + Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype + Viral Load (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight + Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by EVR Type (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Gender (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Race (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Human Immunodeficiency Virus (HIV) Status (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment (EOT) Response (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With EOT Response by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With EVR by Selected Chronic HCV Genotypes (Stage 1)</outcome_measure>
      <outcome_measure>Relapse Rate by HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Study Drug Due to Adverse Events by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Rapid Virologic Response (RVR) (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR Who Achieved SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR Who Achieved SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Liver Fibrosis Stage (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Liver Fibrosis Stage (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Liver Fibrosis Score (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Percentage of Compliance for Participants Achieving SVR Based on Medication Adherence Questionnaire (MAQ) (Stage 2)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724893</url>
  </study>
  <study rank="212">
    <nct_id>NCT02204475</nct_id>
    <title>Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir/Elbasvir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-066</other_id>
      <other_id>2014-001841-25</other_id>
    </other_ids>
    <first_received>July 28, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving SVR12</outcome_measure>
      <outcome_measure>Proportion of TN participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants withdrawing from study treatment due to AEs</outcome_measure>
      <outcome_measure>Proportion of PTF participants achieving SVR12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02204475</url>
  </study>
  <study rank="213">
    <nct_id>NCT01045278</nct_id>
    <title>Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon-alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Region Skane</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>277</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EU-nr 2007-001130-13</other_id>
    </other_ids>
    <first_received>September 11, 2009</first_received>
    <start_date>April 2008</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 1, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the completion rates of HCV treatment with pegylated interferon-alfa-2b and ribavirin in patients who are under opiate maintenance treatment and eligible for HCV therapy.</outcome_measure>
      <outcome_measure>Prevalence of chronic HCV infection in the patient population eligible for part I in the study.</outcome_measure>
      <outcome_measure>Clinical and histological characteristics of chronic hepatitis C.</outcome_measure>
      <outcome_measure>Prevalence of hepatic decompensation and cirrhosis/advanced liver disease.</outcome_measure>
      <outcome_measure>Risk factors for advanced liver disease.</outcome_measure>
      <outcome_measure>Proportion of sustained virological responders, defined as a plasma HVC RNA level below Lower Level of Quantification at 24 week post-treatment.</outcome_measure>
      <outcome_measure>Rates of relapse in opiate drug abuse.</outcome_measure>
      <outcome_measure>Prevalence of depressive symptoms and assessment of quality of life before, under and after HCV treatment.</outcome_measure>
      <outcome_measure>Potential pharmacokinetic interactions between ribavirin and methadone or buprenorphine.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01045278</url>
  </study>
  <study rank="214">
    <nct_id>NCT00146705</nct_id>
    <title>Long Term Follow-up of Pegylated-Interferon Alpha-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">blood samples are taken once</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>266</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>LTFU HBV 99-01</other_id>
    </other_ids>
    <first_received>September 5, 2005</first_received>
    <start_date>May 2005</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>July 31, 2007</last_updated>
    <last_verified>July 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00146705</url>
  </study>
  <study rank="215">
    <nct_id>NCT01760122</nct_id>
    <title>Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University First Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>820</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1211IFN</other_id>
    </other_ids>
    <first_received>December 30, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 28, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with HBeAg seroconversion at week72</outcome_measure>
      <outcome_measure>Proportion of Patients with HBeAg seroconversion at week 12,24,48</outcome_measure>
      <outcome_measure>Proportion fo patients with HBeAg undetectable at week 12, 24, 48, and 72.</outcome_measure>
      <outcome_measure>Average of HBV DNA decline level at week 12, 24,48 and 72</outcome_measure>
      <outcome_measure>Average of HBsAg decline level at week 12, 24, 48 and 72, and Proportion of patients with HBsAg undetectable and HBsAg seroconversion at week 12, 24, 48 and 72.</outcome_measure>
      <outcome_measure>Proportion of patients with ALT normalization at week 12,24, 48 and 72.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01760122</url>
  </study>
  <study rank="216">
    <nct_id>NCT02454764</nct_id>
    <title>'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HBV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenofovir + Interferon alpha 2b</intervention>
      <intervention type="Drug">Tenofovir disoproxil Fumarate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ILBS-HBV-001</other_id>
    </other_ids>
    <first_received>May 22, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>May 2020</completion_date>
    <last_updated>June 26, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained [ 6 months after stopping treatment] HBeAg seroconversion to anti-Hbe on two consecutive assays, at least 1 month apart</outcome_measure>
      <outcome_measure>HBsAg loss</outcome_measure>
      <outcome_measure>Absence of quantifiable serum HBV DNA</outcome_measure>
      <outcome_measure>Development of serious adverse effects, acute hepatitis or hepatic decompensation</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02454764</url>
  </study>
  <study rank="217">
    <nct_id>NCT01581398</nct_id>
    <title>Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>770</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1203IFN</other_id>
    </other_ids>
    <first_received>February 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with sustained virologic response (defined as HCV RNA&lt;15IU/ml at 24 weeks after the end of therapy)</outcome_measure>
      <outcome_measure>Proportion of patients with HCV RNA undetectable (defined as HCV RNA &lt;15IU/ml)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01581398</url>
  </study>
  <study rank="218">
    <nct_id>NCT00215891</nct_id>
    <title>PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection in HIV-Infected Persons</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Interferon a-2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepatitis Resource Network</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
      <collaborator>Subsidiary of Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRN 005</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <last_updated>October 24, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Objectives:</outcome_measure>
      <outcome_measure>Primary</outcome_measure>
      <outcome_measure>To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing therapy).</outcome_measure>
      <outcome_measure>Secondary</outcome_measure>
      <outcome_measure>· To evaluate the safety and tolerability PEG Intron in combination with ribavirin for treatment of Chronic Hepatitis C (CHC) infection in patients co-infected with Human Immunodeficiency Virus (HIV).</outcome_measure>
      <outcome_measure>· To determine the early virologic response of patients receiving PEGIntron plus ribavirin at Treatment Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00215891</url>
  </study>
  <study rank="219">
    <nct_id>NCT00217139</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-05-002</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>September 27, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00217139</url>
  </study>
  <study rank="220">
    <nct_id>NCT00292084</nct_id>
    <title>An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-05-004</other_id>
    </other_ids>
    <first_received>February 13, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>January 17, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load reduction from baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00292084</url>
  </study>
  <study rank="221">
    <nct_id>NCT02089685</nct_id>
    <title>Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Cell Carcinoma</condition>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pembrolizumab</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Biological">Ipilimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>343</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3475-029</other_id>
      <other_id>2013-004072-36</other_id>
    </other_ids>
    <first_received>March 14, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with dose-limiting toxicities (Part 1)</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Number of participants discontinuing study drug because of AEs</outcome_measure>
      <outcome_measure>Progression-free survival (PFS)</outcome_measure>
      <outcome_measure>Overall Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Response</outcome_measure>
      <outcome_measure>Objective response rate (ORR) (Part 1B)</outcome_measure>
      <outcome_measure>ORR (Part 2)</outcome_measure>
      <outcome_measure>Duration of Response (DOR)</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02089685</url>
  </study>
  <study rank="222">
    <nct_id>NCT00031343</nct_id>
    <title>The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">highly active antiretroviral therapy (HAART)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>020139</other_id>
      <other_id>02-I-0139</other_id>
    </other_ids>
    <first_received>March 2, 2002</first_received>
    <start_date>February 2002</start_date>
    <completion_date>April 2004</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>April 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00031343</url>
  </study>
  <study rank="223">
    <nct_id>NCT01121705</nct_id>
    <title>Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg Interferon alpha2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007-00437470</other_id>
    </other_ids>
    <first_received>May 4, 2010</first_received>
    <start_date>January 2007</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>August 9, 2011</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>genotype-3</acronym>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01121705</url>
  </study>
  <study rank="224">
    <nct_id>NCT01364090</nct_id>
    <title>A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1007</other_id>
    </other_ids>
    <first_received>May 31, 2011</first_received>
    <start_date>June 2012</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACTIVATE</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Efficacy</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Treatment Adherence</outcome_measure>
      <outcome_measure>Treatment response (ETR &amp; SVR24)</outcome_measure>
      <outcome_measure>Behavioral and Quality of Life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Norway</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01364090</url>
  </study>
  <study rank="225">
    <nct_id>NCT00305383</nct_id>
    <title>Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viramidine</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-202</other_id>
    </other_ids>
    <first_received>March 17, 2006</first_received>
    <start_date>November 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Efficacy: The proportion of patients with hepatitis C virus (HCV) RNA undetectable or with at least a 2-log drop from baseline at CT Week 4 in the viramidine pre-load group versus the viramidine standard dosing group.</outcome_measure>
      <outcome_measure>Safety: Evaluation of adverse events (AEs).</outcome_measure>
      <outcome_measure>Safety: Physical exams</outcome_measure>
      <outcome_measure>Safety: Vital signs</outcome_measure>
      <outcome_measure>Safety: Laboratory tests</outcome_measure>
      <outcome_measure>Efficacy: HCV RNA Response at CT Week 12, 24, end of treatment and at follow-up Week 24.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00305383</url>
  </study>
  <study rank="226">
    <nct_id>NCT00846430</nct_id>
    <title>Medical Treatment of &quot;High-Risk&quot; Neurofibromas</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neurofibromatosis 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon alpha-2b</intervention>
      <intervention type="Drug">Celecoxib (Celebrex)</intervention>
      <intervention type="Drug">Temozolomide (temodar)</intervention>
      <intervention type="Drug">Vincristine Sulfate (Oncovin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Spectrum Health Hospitals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-260</other_id>
    </other_ids>
    <first_received>January 16, 2009</first_received>
    <start_date>October 2008</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>May 20, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tumor response based on evaluation of symptom assessment, tumor measurements, and MRI studies - Toxicity of treatment combinations based upon laboratory studies and physical examination</outcome_measure>
      <outcome_measure>Psychological toxicity based upon psychological evaluations - Improved quality of life based upon physical examination and performance scales</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00846430</url>
  </study>
  <study rank="227">
    <nct_id>NCT01295515</nct_id>
    <title>Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon Alpha 2b (PEGINTRON)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110057</other_id>
      <other_id>11-I-0057</other_id>
    </other_ids>
    <first_received>February 11, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>This is a non-randomized, single arm pilot study of 10 participants to investigate the effect of interferon alpha on HIV-1 production in HIV-infected individuals with HIV-1 RNA levels of &amp; lt; 50 copies/mL.</outcome_measure>
      <outcome_measure>Investigate HIV-1 genetic variation in individuals undergoing interferon therapy.</outcome_measure>
      <outcome_measure>Investigate the safety and tolerability of PEG INF 2b in HIV-1 infected individuals taking FDA-approved antiretrovirals in combinations recommended by Department of Health and Human Services (DHHS) guidelines.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01295515</url>
  </study>
  <study rank="228">
    <nct_id>NCT01949168</nct_id>
    <title>A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)</intervention>
      <intervention type="Drug">Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection</intervention>
      <intervention type="Drug">Rebetol® (ribavirin), 1000/1200mg by mouth daily</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Vincent's Hospital Melbourne</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme (Australia) Pty Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-6 study</other_id>
    </other_ids>
    <first_received>September 4, 2013</first_received>
    <start_date>September 2013</start_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV-6</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early viral kinetics</outcome_measure>
      <outcome_measure>Rates of virological response</outcome_measure>
      <outcome_measure>Number of patients eligible for Response Guided Therapy</outcome_measure>
      <outcome_measure>Rates of virological breakthrough</outcome_measure>
      <outcome_measure>Rates of SVR12 and relapse</outcome_measure>
      <outcome_measure>Rates of anaemia on treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01949168</url>
  </study>
  <study rank="229">
    <nct_id>NCT01866553</nct_id>
    <title>Nilotinib Plus Pegylated Interferon-α2b in CML</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nilotinib</intervention>
      <intervention type="Drug">Pegylated interferon α-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VU University Medical Center</lead_sponsor>
      <collaborator>Uppsala University Hospital</collaborator>
      <collaborator>Novartis</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NordDutchCML009</other_id>
      <other_id>2012-004321-25</other_id>
      <other_id>NTR 3732</other_id>
    </other_ids>
    <first_received>May 28, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the proportion of patients achieving confirmed MR4.0.</outcome_measure>
      <outcome_measure>the number of patients experiencing grade 3 or more adverse events</outcome_measure>
      <outcome_measure>The proportion of patients who complete the planned 9 months of combination therapy with PegIFN (i.e. to Month 12 assessment).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
      <country>Finland</country>
      <country>Netherlands</country>
      <country>Norway</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01866553</url>
  </study>
  <study rank="230">
    <nct_id>NCT01010646</nct_id>
    <title>Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IFN alfa-2b XL 27 MUI + Ribavirin</intervention>
      <intervention type="Drug">IFN alfa-2b XL 36 MUI + Ribavirin</intervention>
      <intervention type="Drug">IFN peg alfa-2b 1.5 µg/kg + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Flamel Technologies</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-015121-37</other_id>
      <other_id>ANRS HC 23 COAT-IFN</other_id>
    </other_ids>
    <first_received>November 9, 2009</first_received>
    <start_date>March 2010</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COAT IFN</acronym>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral load decrease at Week 4 and Week 12 of treatment with IFN alfa-2b XL 27 MIU, IFN alfa-2b XL 36 MIU and the marketed reference product (PEG IFN alfa-2b 1.5μg/kg) in combination with ribavirin</outcome_measure>
      <outcome_measure>Percentage of patients with early virologic response (EVR) (reduction of at least 2 log viral load) at the end of week 12</outcome_measure>
      <outcome_measure>Percentage of patients with complete early virologic response (EVR) (viral load &lt;15 IU) at the end of the week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01010646</url>
  </study>
  <study rank="231">
    <nct_id>NCT00277238</nct_id>
    <title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic Active</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">Control</intervention>
      <intervention type="Drug">CPG10101</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>113</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B1211002</other_id>
      <other_id>CPG 10101-004</other_id>
    </other_ids>
    <first_received>January 13, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>April 21, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum HCV RNA concentrations, over 12wks, relative to baseline, early virologic response (EVR)</outcome_measure>
      <outcome_measure>Serum HCV RNA concentrations, 6months after treatment completed, relative to baseline, sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Safety and Tolerability: adverse events, vital signs, clinical and laboratory parameters, depression score, physical exam, electrocardiogram (ECG), ophthalmologic exam (if required)</outcome_measure>
      <outcome_measure>Dose exposure</outcome_measure>
      <outcome_measure>Child-Pugh score</outcome_measure>
      <outcome_measure>Serum Biomarkers: cytokines and chemokines, over time, relative to baseline</outcome_measure>
      <outcome_measure>Immunophenotyping profile, over time, relative to baseline, HCV specific immune response, over time, relative to baseline, level of innate immune activation at baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00277238</url>
  </study>
  <study rank="232">
    <nct_id>NCT01095445</nct_id>
    <title>EXtended Therapy in Hepatitis C Genotype 3 Infected Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EXACT-R(3)</other_id>
    </other_ids>
    <first_received>March 26, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 27, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EXACT-R(3)</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>End of treatment response</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01095445</url>
  </study>
  <study rank="233">
    <nct_id>NCT01838772</nct_id>
    <title>HCV Treatment in HIV Co-Infected Patients in Asia</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>amfAR, The Foundation for AIDS Research</lead_sponsor>
      <collaborator>Kirby Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TA010</other_id>
    </other_ids>
    <first_received>April 5, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients with sustained virological response (SVR), defined as an undetectable HCV RNA, 24 weeks after completion of therapy</outcome_measure>
      <outcome_measure>Proportion of patients with Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Proportion of patients with Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Proportion of patients with End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Proportions of patients who discontinue treatment prematurely</outcome_measure>
      <outcome_measure>Clinical and laboratory safety parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Indonesia</country>
      <country>Malaysia</country>
      <country>Thailand</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01838772</url>
  </study>
  <study rank="234">
    <nct_id>NCT01770223</nct_id>
    <title>A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-113</other_id>
      <other_id>2012-002771-33</other_id>
    </other_ids>
    <first_received>January 15, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with sustained virologic response (SVR) at 24 weeks after the end of 48 weeks of study treatment</outcome_measure>
      <outcome_measure>Change from baseline in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01770223</url>
  </study>
  <study rank="235">
    <nct_id>NCT00323505</nct_id>
    <title>A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Myeloma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon</intervention>
      <intervention type="Drug">Interferon-alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Royal Marsden NHS Foundation Trust</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1871</other_id>
    </other_ids>
    <first_received>May 8, 2006</first_received>
    <start_date>March 2001</start_date>
    <completion_date>December 2004</completion_date>
    <last_updated>May 8, 2006</last_updated>
    <last_verified>May 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00323505</url>
  </study>
  <study rank="236">
    <nct_id>NCT01405027</nct_id>
    <title>Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Educational Intervention</intervention>
      <intervention type="Other">Patient education and management skills training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chronic Liver Disease Foundation</lead_sponsor>
      <collaborator>SCRI Development Innovations, LLC</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLDF-MER-001-00</other_id>
      <other_id>20111013</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 22, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>November 17, 2014</firstreceived_results_date>
    <acronym>OPTIMAL</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Duration Compliance Rate</outcome_measure>
      <outcome_measure>Drug Exposure</outcome_measure>
      <outcome_measure>Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.</outcome_measure>
      <outcome_measure>Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01405027</url>
  </study>
  <study rank="237">
    <nct_id>NCT00418054</nct_id>
    <title>Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide plus peginterferon alfa-2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-2022</other_id>
    </other_ids>
    <first_received>January 3, 2007</first_received>
    <start_date>December 2005</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>January 3, 2007</last_updated>
    <last_verified>January 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virologic response</outcome_measure>
      <outcome_measure>2 log drop in serum HCV RNA</outcome_measure>
      <outcome_measure>Change in ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00418054</url>
  </study>
  <study rank="238">
    <nct_id>NCT02247440</nct_id>
    <title>HCV-HIV Co-infected Patient Cohort in Thailand</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon + ribavirin under HIV physician supervision</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut de Recherche pour le Developpement</lead_sponsor>
      <collaborator>Ministry of Health, Thailand</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PHPT-HCV</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>May 24, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 6 months after treatment discontinuation</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Impact of HCV treatment on HIV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02247440</url>
  </study>
  <study rank="239">
    <nct_id>NCT00842205</nct_id>
    <title>Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
      <condition>Nonalcoholic Steatohepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charles University, Czech Republic</lead_sponsor>
      <collaborator>IGA MZ, Czech Republic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGA MZ CR NR9412-3</other_id>
    </other_ids>
    <first_received>February 11, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>February 11, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1. the relation between HO activity and basic virologic and histologic parameters in chronic HCV patients. 2. changes of HO activity within antiviral treatment 3. relation of HO gene polymorphisms to the course of disease</outcome_measure>
      <outcome_measure>Relation of HO gene polymorphisms and UGT1A1*28 polymorphism.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00842205</url>
  </study>
  <study rank="240">
    <nct_id>NCT01443923</nct_id>
    <title>Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>HIV/AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-Interferon-alfa 2B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110253</other_id>
      <other_id>11-I-0253</other_id>
    </other_ids>
    <first_received>September 29, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>February 25, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy, Defined as Sustained Viral Response (SVR) Six Months After the End of Specified Treatment.</outcome_measure>
      <outcome_measure>Change in Early HCV Viral Load Kinetics Between Mono and Co-infected Subjects</outcome_measure>
      <outcome_measure>Safety and Treatment Outcome Measures Stratified by ESA Use</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Are Receiving HAART Who Remain With an HIV RNA &amp; lt; 400 Copies/mL and Those With HIV RNA &amp; gt; 400 Copies/mL at End of Treatment</outcome_measure>
      <outcome_measure>Efficacy (SVR) Rates as Predicted by Viral Response at the End of the 4-week lead-in Therapy With PEG/RBV and Comparison Between HCV Monoinfected and HIV/HCV Coinfected Subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01443923</url>
  </study>
  <study rank="241">
    <nct_id>NCT01457937</nct_id>
    <title>Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Menopause</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon, Ribavirin, Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Modena and Reggio Emilia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudraCT 2011-002459-33</other_id>
    </other_ids>
    <first_received>October 8, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 29, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_BOC</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of sustained virological response in previous treatment failure or naive HCV-positive menopausal women.</outcome_measure>
      <outcome_measure>Early virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01457937</url>
  </study>
  <study rank="242">
    <nct_id>NCT00959699</nct_id>
    <title>A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to Boceprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05411</other_id>
      <other_id>MK-3034-025</other_id>
    </other_ids>
    <first_received>July 29, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 8, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial Medication</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Randomized Participants Who Received At Least One Dose of Boceprevir (Experimental) or Placebo (Control)</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV-RNA at Follow-up Week 12 (FW12)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 HCV-RNA at Treatment Week 4 (TW4)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV Virologic Breakthrough or Incomplete Virologic Response/Rebound</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00959699</url>
  </study>
  <study rank="243">
    <nct_id>NCT00705224</nct_id>
    <title>Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05562</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>August 9, 2011</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Response Following Treatment as Assessed at End of Treatment by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Demonstrated Virological Relapse as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Early Virological Response as Assessed at Visit 2 by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705224</url>
  </study>
  <study rank="244">
    <nct_id>NCT00277758</nct_id>
    <title>Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Interleukin 2</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alpha</intervention>
      <intervention type="Biological">Inteleukin-2</intervention>
      <intervention type="Drug">Ribavirin + Pegylated interferon-alpha</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>00-092</other_id>
      <other_id>UO1 AI48224</other_id>
    </other_ids>
    <first_received>January 12, 2006</first_received>
    <start_date>March 2004</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>March 6, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determination of the safety and tolerability of 12 weeks IL2 monotherapy followed by 48 weeks of IL2 combined with PEG-IFN/RBV</outcome_measure>
      <outcome_measure>Determination of specific immunologic responses to HCV. Immunologic assessment will be performed as the sme time intervals as the assays for plasma virus.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00277758</url>
  </study>
  <study rank="245">
    <nct_id>NCT00084279</nct_id>
    <title>CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>InterMune</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGHC-002</other_id>
    </other_ids>
    <first_received>June 9, 2004</first_received>
    <start_date>April 2004</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>July 1, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virologic response defined as &gt;2 log (base 10) reduction in HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00084279</url>
  </study>
  <study rank="246">
    <nct_id>NCT00230958</nct_id>
    <title>Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viramidine</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-301</other_id>
    </other_ids>
    <first_received>September 29, 2005</first_received>
    <start_date>December 2003</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.</outcome_measure>
      <outcome_measure>- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA at treatment week 24</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24</outcome_measure>
      <outcome_measure>- Safety: Monitoring of adverse events</outcome_measure>
      <outcome_measure>- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00230958</url>
  </study>
  <study rank="247">
    <nct_id>NCT00308048</nct_id>
    <title>14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa 2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ullevaal University Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>435</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03720</other_id>
    </other_ids>
    <first_received>March 27, 2006</first_received>
    <start_date>March 2004</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>July 3, 2011</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) =HCV RNA negativity (&lt;20 IU/ml) six months after end of treatment.</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 6 months after end of treatment.</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 14 or 24 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00308048</url>
  </study>
  <study rank="248">
    <nct_id>NCT00529568</nct_id>
    <title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eltrombopag</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>759</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL108390</other_id>
    </other_ids>
    <first_received>September 12, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>April 19, 2012</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt;75 Gi/L to a Count Greater Than or Equal to (&gt;=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the OL Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00529568</url>
  </study>
  <study rank="249">
    <nct_id>NCT01928511</nct_id>
    <title>Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly</intervention>
      <intervention type="Drug">Nucleos(t)ide analogue therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seng Gee Lim</lead_sponsor>
      <collaborator>Tan Tock Seng Hospital</collaborator>
      <collaborator>Singapore Clinical Research Institute</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>National University Health System, Singapore</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MK4031-398</other_id>
      <other_id>CIRG12may075</other_id>
    </other_ids>
    <first_received>August 21, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>January 8, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWAP</acronym>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in quantitative HBsAg&gt;1 log</outcome_measure>
      <outcome_measure>HBeAg loss</outcome_measure>
      <outcome_measure>HBsAg seroclearance</outcome_measure>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>HBsAg &lt;200 IU/ml</outcome_measure>
      <outcome_measure>undetectable HBV DNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Singapore</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01928511</url>
  </study>
  <study rank="250">
    <nct_id>NCT01023035</nct_id>
    <title>Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Erythropoietin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>687</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06086</other_id>
      <other_id>2009-012782-63</other_id>
    </other_ids>
    <first_received>November 24, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 16, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01023035</url>
  </study>
  <study rank="251">
    <nct_id>NCT01547312</nct_id>
    <title>Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon</intervention>
      <intervention type="Procedure">Liver Samples from FNA</intervention>
      <intervention type="Procedure">Liver Samples from CNB</intervention>
      <intervention type="Procedure">Blood Samples</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">800 mg Grazoprevir</intervention>
      <intervention type="Drug">100 mg Grazoprevir</intervention>
      <intervention type="Procedure">Liver samples from CNB and FNA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-022</other_id>
      <other_id>2011-004978-29</other_id>
    </other_ids>
    <first_received>February 2, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01547312</url>
  </study>
  <study rank="252">
    <nct_id>NCT01463956</nct_id>
    <title>Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
      <condition>Liver Cirrhosis, Experimental</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-Interferon α-2b or Peg-Interferon α-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011- 001089 -17</other_id>
    </other_ids>
    <first_received>October 14, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>Compliance rate.</outcome_measure>
      <outcome_measure>SVR prognosis factors</outcome_measure>
      <outcome_measure>The predictive value of on-treatment HCV RNA on SVR</outcome_measure>
      <outcome_measure>The percentage of virologic failure</outcome_measure>
      <outcome_measure>The percentage of relapse after transplantation</outcome_measure>
      <outcome_measure>Boceprevir resistant mutations</outcome_measure>
      <outcome_measure>Resistant mutations in plasma and liver samples (both explanted liver and graft)</outcome_measure>
      <outcome_measure>Sepsis according to Systemic Inflammatory Response System (SIRS) Criteria</outcome_measure>
      <outcome_measure>Cirrhosis impairment</outcome_measure>
      <outcome_measure>Survival after transplantation</outcome_measure>
      <outcome_measure>Survival rate within one year after liver transplantation</outcome_measure>
      <outcome_measure>The mean time elapsed between registration on the transplantation list and the date of transplantation</outcome_measure>
      <outcome_measure>Measurement of the residual plasma concentration (Cres) of ribavirin</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration Time Curve (AUC) From 0-8h of Boceprevir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Boceprevir</outcome_measure>
      <outcome_measure>Time of Maximum Plasma Concentration (Tmax) of Boceprevir</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Boceprevir</outcome_measure>
      <outcome_measure>Correlation study between the presence of an elevated level of IP-10 during triple therapy and the absence of sustained virologic response</outcome_measure>
      <outcome_measure>Histological severity of HCV recurrence after liver transplantation</outcome_measure>
      <outcome_measure>Insulin Resistance (HOMA-IR)</outcome_measure>
      <outcome_measure>Virological Response in participants with and without Insulin Resistance</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism in the IL28B gene (donor and recipient) and SVR</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism to the ITPA gene and the onset of hemolytic anemia</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01463956</url>
  </study>
  <study rank="253">
    <nct_id>NCT01285050</nct_id>
    <title>Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infection</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anti-HIV Agents</intervention>
      <intervention type="Drug">raltegravir</intervention>
      <intervention type="Drug">Emtricitabine and tenofovir disoproxil fumarate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NA00040361</other_id>
      <other_id>R01DA013806</other_id>
    </other_ids>
    <first_received>January 26, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>April 6, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>HIV RNA</outcome_measure>
      <outcome_measure>ISG</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01285050</url>
  </study>
  <study rank="254">
    <nct_id>NCT01098097</nct_id>
    <title>Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alpha</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>963</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06011</other_id>
    </other_ids>
    <first_received>April 1, 2010</first_received>
    <start_date>June 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>October 17, 2012</firstreceived_results_date>
    <acronym>POMOSCH</acronym>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Incidence of Thrombocytopenia</outcome_measure>
      <outcome_measure>Incidence of Treatment Discontinuations Due to Adverse Events</outcome_measure>
      <outcome_measure>Incidence of Particular Adverse Events Resulting in Treatment Discontinuation</outcome_measure>
      <outcome_measure>Incidence of Dose Modifications Due to Adverse Events</outcome_measure>
      <outcome_measure>Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01098097</url>
  </study>
  <study rank="255">
    <nct_id>NCT00514111</nct_id>
    <title>Factors Associated to Success of Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated-interferon, conventional-interferon, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UPECLIN HC FM Botucatu Unesp</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>upeclin/HC/FMB-Unesp-16</other_id>
    </other_ids>
    <first_received>August 8, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>March 19, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00514111</url>
  </study>
  <study rank="256">
    <nct_id>NCT00132210</nct_id>
    <title>Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bonn</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BN-102/02</other_id>
    </other_ids>
    <first_received>August 17, 2005</first_received>
    <start_date>September 2002</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 20, 2010</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negative hepatitis C ribonucleic acid (HCV-RNA) in peripheral serum</outcome_measure>
      <outcome_measure>Normal liver enzymes</outcome_measure>
      <outcome_measure>Negative HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00132210</url>
  </study>
  <study rank="257">
    <nct_id>NCT00543244</nct_id>
    <title>Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200709053R</other_id>
    </other_ids>
    <first_received>October 10, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>November 20, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00543244</url>
  </study>
  <study rank="258">
    <nct_id>NCT00887081</nct_id>
    <title>Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemoglobinopathies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera V. Cervello</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AOVCervello1</other_id>
    </other_ids>
    <first_received>April 21, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>April 22, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNRIBAHE</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A sustained virological response (SVR), defined as absence of HCV RNA in serum by a highly sensitive test at the end of treatment and 6 months late.</outcome_measure>
      <outcome_measure>Early virological response (EVR) , defined as the loss of HCV RNA during the first 12 weeks of therapy; main side effects enclosing changes in blood transfusion requirement; increase in ferritin levels and variations in chelation treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00887081</url>
  </study>
  <study rank="259">
    <nct_id>NCT01402583</nct_id>
    <title>Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG IFN/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Prof. Facchinetti Fabio</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>University of Modena and Reggio Emilia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RSO-321</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>October 20, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_EPID</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01402583</url>
  </study>
  <study rank="260">
    <nct_id>NCT00723645</nct_id>
    <title>Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>279</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05181</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>November 26, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>March 23, 2012</firstreceived_results_date>
    <acronym>FAST-4</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed After EOT at Week 72 (Late Relapser)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723645</url>
  </study>
  <study rank="261">
    <nct_id>NCT01066793</nct_id>
    <title>PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2272</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21020</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01066793</url>
  </study>
  <study rank="262">
    <nct_id>NCT01066819</nct_id>
    <title>PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1611</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21542</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>January 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Kansas</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>West Virginia</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01066819</url>
  </study>
  <study rank="263">
    <nct_id>NCT01579474</nct_id>
    <title>Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335 high dose</intervention>
      <intervention type="Drug">BI 201335 low dose</intervention>
      <intervention type="Drug">BI 201335 high dose</intervention>
      <intervention type="Drug">BI 201335 high dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.54</other_id>
    </other_ids>
    <first_received>April 12, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients With Investigator Defined Drug-related Adverse Events</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR12), Defined as Plasma HCV RNA Undetectable at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR24), Defined as Plasma HCV RNA Undetectable at 24 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS), Defined as Plasma HCV RNA &lt;25 IU/mL at Week 4 and HCV RNA Undetectable at Week 8</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01579474</url>
  </study>
  <study rank="264">
    <nct_id>NCT00883844</nct_id>
    <title>PEG-IFN in HBV Patients With Incomplete Response to NA</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nucleos(t)ide analogue treatment with a peginterferon add-on strategy</intervention>
      <intervention type="Drug">Nucleos(t)ide analogue treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV09-03</other_id>
    </other_ids>
    <first_received>April 17, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 18, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PADD</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained response defined as HBeAg loss and HBV DNA level &lt; 200 IU/mL</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00883844</url>
  </study>
  <study rank="265">
    <nct_id>NCT01912495</nct_id>
    <title>Dutch Acute HCV in HIV Study (DAHHS)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Erasmus Medical Center</lead_sponsor>
      <collaborator>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</collaborator>
      <collaborator>Onze Lieve Vrouwe Gasthuis</collaborator>
      <collaborator>UMC Utrecht</collaborator>
      <collaborator>University Medical Center Groningen</collaborator>
      <collaborator>Maastricht University Medical Center</collaborator>
      <collaborator>Rijnstate Hospital</collaborator>
      <collaborator>Slotervaart Hospital</collaborator>
      <collaborator>Radboud University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL44825.078.13</other_id>
    </other_ids>
    <first_received>July 29, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DAHHS</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Responds(SVR) 12 weeks of follow up after the end of all therapy for the Rapid Viral Response at week 4(RVR4) population.</outcome_measure>
      <outcome_measure>SVR 12 weeks after the end of all therapy in the entire study population (with or without RVR4).</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients with already a RVR at week 1.</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients that started therapy ≤12weeks after the presumed HCV infection date versus those after 12 weeks.</outcome_measure>
      <outcome_measure>Alterations of biomarkers by therapy induced viral eradication: Viral sequencing, mutation analysis, gene expression analysis, and RNA analysis.</outcome_measure>
      <outcome_measure>Safety: Treatment related (serious) adverse events ((S)AE) and treatment discontinuation for (S)AE.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01912495</url>
  </study>
  <study rank="266">
    <nct_id>NCT00006249</nct_id>
    <title>Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma (Skin)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">pegylated interferon alfa</intervention>
      <intervention type="Procedure">adjuvant therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>European Organisation for Research and Treatment of Cancer - EORTC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1258</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EORTC-18991</other_id>
    </other_ids>
    <first_received>September 11, 2000</first_received>
    <start_date>June 2000</start_date>
    <last_updated>February 9, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>distant-metastasis free-survival (DMFS)</outcome_measure>
      <outcome_measure>survival</outcome_measure>
      <outcome_measure>toxicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>Croatia</country>
      <country>Czech Republic</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Slovenia</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00006249</url>
  </study>
  <study rank="267">
    <nct_id>NCT01949805</nct_id>
    <title>Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-P-IFN-alpha-2b (AOP2014)</intervention>
      <intervention type="Drug">Hydroxyurea</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AOP Orphan Pharmaceuticals AG</lead_sponsor>
      <collaborator>PharmaEssentia (Co-Sponsor for USA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>256</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PROUD-PV</other_id>
      <other_id>2012-005259-18</other_id>
    </other_ids>
    <first_received>September 6, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>April 17, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PROUD-PV</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease response rate</outcome_measure>
      <outcome_measure>Disaese response</outcome_measure>
      <outcome_measure>JAK2 allelic burden changes</outcome_measure>
      <outcome_measure>time to response</outcome_measure>
      <outcome_measure>duration of response</outcome_measure>
      <outcome_measure>number of phlebotomies</outcome_measure>
      <outcome_measure>blood parameters</outcome_measure>
      <outcome_measure>spleen size</outcome_measure>
      <outcome_measure>disease related symptoms</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
      <outcome_measure>protocol-specific adverse events of special interest</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01949805</url>
  </study>
  <study rank="268">
    <nct_id>NCT01193699</nct_id>
    <title>Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-P-INF alpha-2b (P1101)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AOP Orphan Pharmaceuticals AG</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P11012010</other_id>
    </other_ids>
    <first_received>September 1, 2010</first_received>
    <start_date>August 2010</start_date>
    <last_updated>February 26, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGINVERA</acronym>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum tolerated dose (MTD)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01193699</url>
  </study>
  <study rank="269">
    <nct_id>NCT01465516</nct_id>
    <title>Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>38950</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>June 27, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR based on intention to treat analysis</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>BDI II score 31 or above</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01465516</url>
  </study>
  <study rank="270">
    <nct_id>NCT00027742</nct_id>
    <title>Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Intraocular Melanoma</condition>
      <condition>Melanoma (Skin)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">pegylated interferon alfa</intervention>
      <intervention type="Drug">temozolomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>01-005</other_id>
      <other_id>CDR0000069062</other_id>
      <other_id>NCI-G01-2031</other_id>
    </other_ids>
    <first_received>December 7, 2001</first_received>
    <start_date>May 2001</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>June 4, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2005</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00027742</url>
  </study>
  <study rank="271">
    <nct_id>NCT00006039</nct_id>
    <title>Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoma</condition>
      <condition>Small Intestine Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">pegylated interferon alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>99-101</other_id>
      <other_id>CDR0000068054</other_id>
      <other_id>NCI-G00-1814</other_id>
    </other_ids>
    <first_received>July 5, 2000</first_received>
    <start_date>December 1999</start_date>
    <completion_date>March 2001</completion_date>
    <last_updated>June 17, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2001</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00006039</url>
  </study>
  <study rank="272">
    <nct_id>NCT01718301</nct_id>
    <title>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
      <condition>COINFECTION</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Anna Cruceta</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca Biomédica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOC-HIV</other_id>
      <other_id>2012-003984-23</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOC-HIV</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Achievement of sustained virological response (SVR) at week 24</outcome_measure>
      <outcome_measure>Achievement of sustained virological response at weeks 2,4,8,12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at FW 12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization.</outcome_measure>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Resistance of HCV after boceprevir (BOC) containing regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718301</url>
  </study>
  <study rank="273">
    <nct_id>NCT00556504</nct_id>
    <title>The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCM-700C</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TCM Biotech International Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-700-01-04</other_id>
    </other_ids>
    <first_received>November 8, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 4, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 5, 2013</firstreceived_results_date>
    <acronym>TCM-700C</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>ALT Response</outcome_measure>
      <outcome_measure>Sustained ALT Response</outcome_measure>
      <outcome_measure>Combined ALT and Virologic Response</outcome_measure>
      <outcome_measure>Immune Cell Normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00556504</url>
  </study>
  <study rank="274">
    <nct_id>NCT01625793</nct_id>
    <title>Inflammation, Stress &amp; Social Behavior: Using Ecological Assessments &amp; Model Systems to Enhance Relevance to Health Outcomes</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon-alpha</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Arizona</lead_sponsor>
      <collaborator>Emory University</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0166-02</other_id>
      <other_id>5R01AT007297-03</other_id>
    </other_ids>
    <first_received>June 11, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>July 18, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent time laughing</outcome_measure>
      <outcome_measure>Percent time expressing empathy for others</outcome_measure>
      <outcome_measure>Percent of time spent in substantive conversations</outcome_measure>
      <outcome_measure>Percent of time spent alone</outcome_measure>
      <outcome_measure>Cortisol concentrations in blood in response to stress test</outcome_measure>
      <outcome_measure>Interleukin (IL)-6 concentrations in the blood in response to stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of interleukin-6 and tumor necrosis factor-alpha type II receptors in response to a stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of inflamcortisol in response to a stress test</outcome_measure>
      <outcome_measure>Wake time after sleep onset measured by actigraphy</outcome_measure>
      <outcome_measure>Sleep latency by measured by actigraphy</outcome_measure>
      <outcome_measure>Total sleep time by actigraphy</outcome_measure>
      <outcome_measure>Sleep efficiency by actigraphy</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Depression Scale and Inventory of Depressive Symptomatology (SIGH-IDS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625793</url>
  </study>
  <study rank="275">
    <nct_id>NCT01140997</nct_id>
    <title>Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University People's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>211</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1006IFN</other_id>
    </other_ids>
    <first_received>June 8, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>January 31, 2013</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGIFN</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01140997</url>
  </study>
  <study rank="276">
    <nct_id>NCT01889849</nct_id>
    <title>Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Viral Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIP 48</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ASCLIN 003/2009</other_id>
    </other_ids>
    <first_received>June 19, 2013</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>June 28, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety Assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01889849</url>
  </study>
  <study rank="277">
    <nct_id>NCT02112630</nct_id>
    <title>Boceprevir in End Stage Renal Disease (ESRD)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">P-IFN alfa 2a</intervention>
      <intervention type="Drug">P-IFN alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AAAL5200</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who achieve sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02112630</url>
  </study>
  <study rank="278">
    <nct_id>NCT01403181</nct_id>
    <title>Effect of Boceprevir on HCV-specific T Cell Responses</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliero-Universitaria di Parma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AZOSPA</other_id>
    </other_ids>
    <first_received>July 26, 2011</first_received>
    <start_date>April 2012</start_date>
    <last_updated>November 5, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Boce-Par</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Levels of HCV-specific T cell functions before, during and after therapy to measure functional restoration induced by therapy</outcome_measure>
      <outcome_measure>Correlation of quality and intensity of pre-treatment HCV-specific T cell responses with outcome of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01403181</url>
  </study>
  <study rank="279">
    <nct_id>NCT02430181</nct_id>
    <title>Lonafarnib With and Without Ritonavir in HDV (LOWR-1)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis D Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lonafarnib</intervention>
      <intervention type="Drug">peginterferon</intervention>
      <intervention type="Drug">Ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eiger BioPharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EIG-300</other_id>
      <other_id>Application #1128309</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>November 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>April 25, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>LOWR-1</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in quantitative serum HDV RNA levels after 28-84 days of lonafarnib therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02430181</url>
  </study>
  <study rank="280">
    <nct_id>NCT00142103</nct_id>
    <title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic Active</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">Control</intervention>
      <intervention type="Drug">CPG10101</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B1211001</other_id>
      <other_id>CPG10101-003</other_id>
    </other_ids>
    <first_received>August 31, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>May 13, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events, vital signs, clinical and laboratory parameters, physical exam, ECG</outcome_measure>
      <outcome_measure>Serum HCV RNA concentrations: Serum HCV concentrations over time to baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00142103</url>
  </study>
  <study rank="281">
    <nct_id>NCT01529073</nct_id>
    <title>Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Juan Macías</lead_sponsor>
      <collaborator>Spanish National Health System</collaborator>
      <collaborator>Andaluz Health Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NTZSPA001</other_id>
      <other_id>2010-024336-42</other_id>
    </other_ids>
    <first_received>February 5, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>January 13, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Safety of Peg-interferon plus ribavirin plus nitazoxanide</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01529073</url>
  </study>
  <study rank="282">
    <nct_id>NCT02060058</nct_id>
    <title>Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stop trial intervention for boceprevir, PEG-IFN and RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
      <collaborator>National Taiwan University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUHIRB-2013-10-03 (I)</other_id>
    </other_ids>
    <first_received>January 27, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>February 9, 2014</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOLERO-CB</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary endpoint of this clinical trial-SVR and FAS for HCV RNA</outcome_measure>
      <outcome_measure>Key secondary endpoint of this clinical trial-SVR in mITT and HBV DNA surge</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02060058</url>
  </study>
  <study rank="283">
    <nct_id>NCT01636778</nct_id>
    <title>Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB-497115-GR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>116101</other_id>
    </other_ids>
    <first_received>July 5, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt; 80 Gi/L to a Count &gt;=100 Gi/L During Part 1</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Counts Maintained at &gt;=50 Gi/L During Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 1</outcome_measure>
      <outcome_measure>Time in Weeks to Achieve Platelet Count &gt;= 100 Gi/L</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Minimum Platelet Count on Antiviral Therapy</outcome_measure>
      <outcome_measure>Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Antiviral Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points In Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Weight at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc</outcome_measure>
      <outcome_measure>Mean Change From Baseline in BMI at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean BMI at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01636778</url>
  </study>
  <study rank="284">
    <nct_id>NCT00301509</nct_id>
    <title>Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis, Experimental</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>630/DS</other_id>
    </other_ids>
    <first_received>March 10, 2006</first_received>
    <start_date>January 2002</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>March 10, 2006</last_updated>
    <last_verified>December 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00301509</url>
  </study>
  <study rank="285">
    <nct_id>NCT01377909</nct_id>
    <title>HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">statin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bader, Ted, M.D.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Bader 15859</other_id>
    </other_ids>
    <first_received>June 20, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>August 21, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in peginterferon response as measured by change in HCV RNA levels</outcome_measure>
      <outcome_measure>The response of interferon stimulated genes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Oklahoma</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01377909</url>
  </study>
  <study rank="286">
    <nct_id>NCT00422838</nct_id>
    <title>Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver</condition>
      <condition>Immunology</condition>
      <condition>Regulation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fine-needle aspiration biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CIRES</other_id>
    </other_ids>
    <first_received>January 15, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>September 6, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CIRES</acronym>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00422838</url>
  </study>
  <study rank="287">
    <nct_id>NCT00148863</nct_id>
    <title>Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2a (drug)</intervention>
      <intervention type="Drug">Ribavirin (drug)</intervention>
      <intervention type="Drug">Interferon gamma (drug)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>InterMune</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-005033-19</other_id>
      <other_id>ANRS HC16 Gammatri</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 29, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)</outcome_measure>
      <outcome_measure>Virological response at W72</outcome_measure>
      <outcome_measure>Biochemical response at W72 (ALT below normal value)</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Immunologic response (CD4 and CD8 HCV specific)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00148863</url>
  </study>
  <study rank="288">
    <nct_id>NCT00120835</nct_id>
    <title>Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">valopicitabine</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV-08A-003</other_id>
    </other_ids>
    <first_received>July 11, 2005</first_received>
    <start_date>July 2004</start_date>
    <last_updated>June 9, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00120835</url>
  </study>
  <study rank="289">
    <nct_id>NCT00996216</nct_id>
    <title>Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
      <intervention type="Drug">Antiviral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>108392</other_id>
    </other_ids>
    <first_received>October 1, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>October 10, 2013</firstreceived_results_date>
    <acronym>ENABLE-ALL</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With a logMAR Change &gt;=0.15 During Parts 1 and 2</outcome_measure>
      <outcome_measure>Platelet Counts at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Particpants Who Initiated Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Pakistan</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Hawaii</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00996216</url>
  </study>
  <study rank="290">
    <nct_id>NCT01959633</nct_id>
    <title>Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vemurafenib</intervention>
      <intervention type="Drug">Peg-interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fondazione Melanoma Onlus</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VEMUPLINT</other_id>
    </other_ids>
    <first_received>September 27, 2013</first_received>
    <start_date>March 2014</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VEMUPLINT</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of Objective tumor responses</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01959633</url>
  </study>
  <study rank="291">
    <nct_id>NCT00226447</nct_id>
    <title>Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon</intervention>
      <intervention type="Drug">Lamivudine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03227</other_id>
    </other_ids>
    <first_received>September 23, 2005</first_received>
    <start_date>December 2002</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>October 23, 2008</last_updated>
    <last_verified>October 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBV DNA reduction at week 52</outcome_measure>
      <outcome_measure>Normalization of ALT &amp; negative HBV DNA at EOT, negative HBV DNA at EOT &amp; 24 weeks after cessation of treatment, normalization of ALT at the end of treatment and 24 weeks after the cessation of treatment, Safety of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00226447</url>
  </study>
  <study rank="292">
    <nct_id>NCT02523638</nct_id>
    <title>Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AOP Orphan Pharmaceuticals AG</lead_sponsor>
      <collaborator>PharmaEssentia Corporation (Co-Sponsor for USA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEN-PV</other_id>
      <other_id>2014-001356-31</other_id>
    </other_ids>
    <first_received>June 12, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>November 5, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEN-PV</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate ease of self-administration of AOP2014</outcome_measure>
      <outcome_measure>Adverse Event</outcome_measure>
      <outcome_measure>number of phlebotomies</outcome_measure>
      <outcome_measure>Disease response</outcome_measure>
      <outcome_measure>blood parameters</outcome_measure>
      <outcome_measure>spleen size</outcome_measure>
      <outcome_measure>disease related symptoms</outcome_measure>
      <outcome_measure>protocol-specific adverse events of special interest</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Slovakia</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02523638</url>
  </study>
  <study rank="293">
    <nct_id>NCT02218047</nct_id>
    <title>AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Proline-interferon alpha-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AOP Orphan Pharmaceuticals AG</lead_sponsor>
      <collaborator>PharmaEssentia (Co-Sponsor for USA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CONTINUATION-PV</other_id>
      <other_id>2014-001357-17</other_id>
    </other_ids>
    <first_received>August 14, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>June 12, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CONTI-PV</acronym>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hct level of 40 - 42% without phlebotomies.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02218047</url>
  </study>
  <study rank="294">
    <nct_id>NCT01062659</nct_id>
    <title>Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Ulm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCell</other_id>
    </other_ids>
    <first_received>February 3, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01062659</url>
  </study>
  <study rank="295">
    <nct_id>NCT00845065</nct_id>
    <title>Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05685</other_id>
    </other_ids>
    <first_received>February 13, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>SVR Rate in the Modified Intent-to-Treat (mITT) Population</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12</outcome_measure>
      <outcome_measure>Mean Log Change From Baseline to TW 4 in Viral Load by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00845065</url>
  </study>
  <study rank="296">
    <nct_id>NCT00110799</nct_id>
    <title>SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
      <condition>Thrombocytopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB497115</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL102357</other_id>
    </other_ids>
    <first_received>May 13, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment response, assessed by the proportion of subjects with a shift from baseline platelet count (20, 000 to &lt;70,000µL) to =100,000/µL after 4 weeks of study treatment.</outcome_measure>
      <outcome_measure>Mean increase in platelet counts and markers of thrombopoiesis. Safety and tolerability, population PK, pharmacodynamics. Effect of antiviral outcome measures during and after therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00110799</url>
  </study>
  <study rank="297">
    <nct_id>NCT02101177</nct_id>
    <title>Evaluation of the National Treatment Program of Hepatitis C in Egypt</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
      <collaborator>National Hepatology &amp; Tropical Medicine Research Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12291</other_id>
    </other_ids>
    <first_received>March 26, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 22, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>eNTC</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Estimate &quot;real life&quot; Sustained Virological Response rate</outcome_measure>
      <outcome_measure>Compare the efficacy of Reiferon®, a biosimilar produced by a local company, Minapharm©, to that of other pegylated interferon of known efficacy (Pegasys®, Pegintron®)</outcome_measure>
      <outcome_measure>Understand the determinants of not returning for follow-up among defaulting patients</outcome_measure>
      <outcome_measure>Optimize selection criteria for patients to be enrolled in the National Treatment Program</outcome_measure>
      <outcome_measure>Estimate &quot;real life&quot; Response rate at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02101177</url>
  </study>
  <study rank="298">
    <nct_id>NCT00071916</nct_id>
    <title>Racial Difference in HCV/Host Interactions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>00-091</other_id>
    </other_ids>
    <first_received>November 4, 2003</first_received>
    <start_date>March 2001</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 28, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Determine if there is a difference in interferon-induced signaling between patients that respond to therapy and those that do not.</outcome_measure>
      <outcome_measure>Measure and compare the sustained virologic response to standard treatment for hepatitis C between African American (AA) and non AA patients.</outcome_measure>
      <outcome_measure>Determine how human leukocyte antigen (HLA) class II-dependent immune regulation and T cell specificities affect differences in immune responses to hepatitis C (HCV) and response to therapy in African American (AA) patients compared to non AA patients.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arkansas</state>
      <state>Tennessee</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00071916</url>
  </study>
  <study rank="299">
    <nct_id>NCT01909401</nct_id>
    <title>Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1301010500</other_id>
    </other_ids>
    <first_received>June 13, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 23, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of individuals who can remain HCV RNA undetected 6 months post orthotopic liver transplant after receiving peginterferon, ribavirin, and boceprevir.</outcome_measure>
      <outcome_measure>Safety and efficacy of peginterferon, ribavirin, and boceprevir in patients with genotype I undergoing orthotopic liver transplant for cirrhosis and/or hepatocellular carcinoma.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Indiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01909401</url>
  </study>
  <study rank="300">
    <nct_id>NCT00317746</nct_id>
    <title>Trial of Citalopram for the Prevention of Depression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Citalopram</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Marina Klein</lead_sponsor>
      <collaborator>Ontario HIV Treatment Network</collaborator>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>CIHR Canadian HIV Trials Network</collaborator>
      <collaborator>McGill University Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTN194</other_id>
      <other_id>Schering #2229</other_id>
    </other_ids>
    <first_received>April 21, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>April 4, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PICCO</acronym>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome is the average proportion of PEG-IFN and ribavirin doses received in participants receiving citalopram compared with placebo</outcome_measure>
      <outcome_measure>A second major objective is to compare arms with respect to the rate of moderate-to-severe depressive symptoms during the first 24 weeks of therapy.</outcome_measure>
      <outcome_measure>Secondary measures will assess impact of citalopram versus placebo on anxiety, neurocognitive function, quality of life and adherence to therapy. HCV and HIV control will also be examined.</outcome_measure>
      <outcome_measure>Substudies aimed at understanding the pathogenesis of neuropsychiatric side effects and neurocognitive function in this population will be performed.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00317746</url>
  </study>
  <study rank="301">
    <nct_id>NCT00548847</nct_id>
    <title>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GM-CSF, Interferon-α-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>Bayer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00002219</other_id>
      <other_id>2219</other_id>
    </other_ids>
    <first_received>October 22, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the efficacy of GM-CSF and pegylated interferon-alpha 2b when administered to patients with AML, ALL, blast phase CML, and MDS relapse after allogeneic transplantation, defined as progression-free survival of &gt; 33% at 3 months</outcome_measure>
      <outcome_measure>To evaluate overall survival at 6 months; evaluate overall responses; perform lab experiments to test hypothesis that exposure to interferon-alpha and GM-CSF up-regulates co-stimulatory molecule expression on relapsed acute leukemia cells</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00548847</url>
  </study>
  <study rank="302">
    <nct_id>NCT00621439</nct_id>
    <title>Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ocular Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interfon Alpha 2B</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00002566</other_id>
    </other_ids>
    <first_received>February 11, 2008</first_received>
    <start_date>March 2007</start_date>
    <last_updated>November 28, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evidence of anti-melanoma natural killer cell boost</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00621439</url>
  </study>
  <study rank="303">
    <nct_id>NCT01178996</nct_id>
    <title>Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Thymosin alpha 1</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">PEGinterferon alfa2a</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>sigma-tau i.f.r. S.p.A.</lead_sponsor>
      <collaborator>SciClone Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>552</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ST1472-DM-03-004</other_id>
      <other_id>2004-001277-25</other_id>
    </other_ids>
    <first_received>August 9, 2010</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>August 9, 2010</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Sustained Biochemical Response (SBR)</outcome_measure>
      <outcome_measure>End of Treatment Biochemical Response (EBR)</outcome_measure>
      <outcome_measure>End of Treatment Virological Response [EVR]</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01178996</url>
  </study>
  <study rank="304">
    <nct_id>NCT00241618</nct_id>
    <title>Timing and Duration of Acute Hepatitis C Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha 2</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
      <collaborator>University Hospital Freiburg</collaborator>
      <collaborator>Beth Israel Deaconess Medical Center</collaborator>
      <collaborator>Alexander von Humboldt Association</collaborator>
      <collaborator>Fulbright</collaborator>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>TEMPUS</collaborator>
      <collaborator>International Society for Infectious Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>994058402</other_id>
      <other_id>AI054887</other_id>
      <other_id>AI41563</other_id>
      <other_id>Fulbright</other_id>
      <other_id>TEMPUS</other_id>
      <other_id>ISID</other_id>
    </other_ids>
    <first_received>October 18, 2005</first_received>
    <start_date>January 2002</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>September 7, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response rate in treatment group versus control</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response at week 4</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00241618</url>
  </study>
  <study rank="305">
    <nct_id>NCT00856804</nct_id>
    <title>Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>University of Seville</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRITAL</other_id>
    </other_ids>
    <first_received>March 3, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>March 5, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TRITAL</acronym>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological response at week 12</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after the end of therapy</outcome_measure>
      <outcome_measure>Safety of using thalidomide together with SOC.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00856804</url>
  </study>
  <study rank="306">
    <nct_id>NCT00211692</nct_id>
    <title>Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">consensus interferon (Interferon Alfacon-1) and ribavirin</intervention>
      <intervention type="Drug">Consensus Interferon alfa (CIFN) and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Minneapolis Veterans Affairs Medical Center</lead_sponsor>
      <collaborator>Minnesota Veterans Research Institute</collaborator>
      <collaborator>InterMune</collaborator>
      <collaborator>Kadmon Pharmaceuticals</collaborator>
      <collaborator>VA Office of Research and Development</collaborator>
      <collaborator>San Diego Veterans Healthcare System</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MVRI001</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>November 20, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>August 1, 2011</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing Early From Study Treatment</outcome_measure>
      <outcome_measure>Participants Achieving SVR Categorized by Time of Response</outcome_measure>
      <outcome_measure>Overall Number of Serious Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00211692</url>
  </study>
  <study rank="307">
    <nct_id>NCT01360268</nct_id>
    <title>The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metabolic Syndrome</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Merck (MISP) # 38846</other_id>
    </other_ids>
    <first_received>May 24, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>May 24, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01360268</url>
  </study>
  <study rank="308">
    <nct_id>NCT01826981</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF FDC</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>362</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0122</other_id>
    </other_ids>
    <first_received>April 1, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with SVR through posttreatment Week 24</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic failure and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01826981</url>
  </study>
  <study rank="309">
    <nct_id>NCT00993122</nct_id>
    <title>Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin pre-treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Roma La Sapienza</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin Pre-treatment</other_id>
    </other_ids>
    <first_received>October 8, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>June 19, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RBV</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV-RNA level, Transaminases level</outcome_measure>
      <outcome_measure>liver biopsy and Transient elastography at baseline and after six month since therapy conclusion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00993122</url>
  </study>
</search_results>
